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RESUMO 
A doença de Parkinson (PD, do inglês “Parkinson’s disease”) é uma patologia 
neurodegenerativa crónica e progressiva, caracterizada pela perda seletiva dos neurónios 
dopaminérgicos nigroestriatais. As manifestações clínicas desta doença neurodegenerativa 
incluem dificuldades motoras, instabilidade postural, bradicinésia, tremor de repouso, 
dificuldades na marcha e rigidez muscular. A evidência neuropatológica da doença é a intensa e 
progressiva perda dos neurónios dopaminérgicos que contêm neuromelanina na substantia nigra 
pars compacta (SNpc) e a presença de corpos de Lewy (LB), maioritariamente constituídos por 
α-sinucleína (α-syn, do inglês “α-synuclein”). Vários mecanismos têm sido propostos para 
explicar o processo neurodegenerativo nos neurónios nigroestriatais, incluindo a disfunção 
mitocondrial e o stresse oxidativo. Estudos anteriores demonstraram um aumento dos níveis de 
ferro (Fe) na SN de cérebros de doentes de Parkinson, implicando a ocorrência de stresse 
oxidativo no processo neurodegenerativo. Contudo, atualmente não existe um tratamento 
neuroprotetor efetivo para a PD. 
De acordo com a literatura, a agregação e o estado de fosforilação da proteína α-syn 
desempenham um papel importante na patogénese da PD. Alguns estudos demonstraram que a 
α-syn depositada nos LBs está altamente fosforilada no resíduo de serina (Ser)129 (quase 90% 
da α-syn), atribuindo um papel importante à fosforilação na agregação da α-syn e na formação 
dos LBs; contudo o seu papel na neurotoxicidade ainda permanece controverso. Um grupo de 
cinases parece ser responsável pela fosforilação da α-syn. Neste grupo de cinases estão incluídas 
as polo-like kinases (PLK1 e PLK2), casein kinases (CK-1 e CK-2) e a leucine-rich repeat 
kinase 2 (LRRK2). Por outro lado, evidências anteriores sugerem que o GDNF (do inglês “glial-
derived neurotrophic factor”) pode oferecer uma potencial proteção terapêutica contra esta 
doença. Assim, o objetivo deste estudo foi avaliar o papel de tais cinases (através da sua 
inibição com compostos potencialmente seletivos) e do GDNF na regulação da fosforilação da 
Ser129 da α-syn em células expostas a Fe (um indutor do stresse oxidativo). Além disso, 
avaliámos o efeito dos inibidores, Fe e GDNF na toxicidade celular. Para tal, usámos células 
humanas derivadas de neuroblastoma, as células SH-SY5Y, que sobre-expressam de forma 
condicionada a α-syn wild-type (WT), através de um sistema de expressão Tet-Off regulado por 
doxiciclina (Dox). 
Os nossos resultados demonstraram que a sobre-expressão da α-syn despoletada na 
ausência da Dox, induziu um decréscimo na viabilidade celular, quando comparado com as 
células incubadas com Dox, avaliada pelo método de Alamar Blue. Estes resultados sugeriram 
que a produção anormal de α-syn é tóxica. Também mostrámos que, com a exceção dos 
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inibidores das PLKs, concentrações nanomolares dos inibidores de cinases conduziram a uma 
percentagem aceitável de células viáveis. Além disso, a avaliação da integridade da membrana 
plasmática e da atividade da caspase-3 em células expostas aos inibidores seletivos, a FeSO4 
(Fe, 500µM) e GDNF (20 ng/ml), não revelou efeitos citotóxicos significativos sobre as células, 
quando comparado com o respetivo controlo. Demonstrámos ainda que o GDNF induziu a 
ativação precoce da via de sinalização PI-3K/Akt, tal como demonstrado pelo aumento dos 
níveis de fosforilação da Akt 10 min após a incubação com GDNF. É interessante notar que, a 
exposição ao Fe ou GDNF durante 2 h aumentou os níveis de fosforilação da α-syn na Ser129. 
Contudo, a pré-incubação de GDNF preveniu a fosforilação da α-syn induzida por Fe. Esta 
observação sugere que o GDNF é importante para reduzir a fosforilação da α-syn induzida pelo 
stresse oxidativo. Por fim, a pré-incubação das células com os inibidores da LRRK2 ou CK-2 
(em particular), seguido da exposição a Fe, impediu o aumento da fosforilação da α-syn 
induzida pelo Fe. 
Os resultados apresentados neste trabalho parecem indicar que a CK-2 está entre as 
potenciais cinases responsáveis pela fosforilação do resíduo de Ser129 da α-syn. Do mesmo 
modo, o GDNF parece ser capaz de contrariar o aumento da fosforilação da α-syn despoletado 
pelo Fe, o que pode depender da ativação da via de sinalização intracelular PI-3K/Akt. Tendo 
em conta que a fosforilação da α-syn parece desempenhar um papel importante na patogénese 
da doença, estas estratégias podem representar uma solução terapêutica promissora na PD. 
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ABSTRACT 
Parkinson’s disease (PD) is a chronic progressive neurodegenerative disorder which 
pathology is characterized by a profound and selective loss of nigrostriatal dopaminergic 
neurons. Clinical manifestations of this neurodegenerative disease include motor impairments, 
postural instability, bradykinesia, resting tremor, gait difficulties and rigidity. The 
neuropathological evidence of the disease are the progressive and intense loss of neuromelanin-
containing dopaminergic neurons in the substantia nigra pars compacta (SNpc) and the 
presence of Lewy bodies (LB), mainly composed of α-synuclein (α-syn). Several mechanisms 
have been proposed to be implicated in the neurodegeneration of SNpc neurons, including 
mitochondrial dysfunction and oxidative stress. Previous studies have reported an increase in 
iron (Fe) levels in the SN of PD brains, implicating oxidative stress as an important process of 
cell fate. However, currently there is no neuroprotective effective treatment for PD. 
Previous evidences have shown that α-syn aggregation and phosphorylation states play an 
important role in PD pathogenesis. Some reports demonstrated that α-syn deposited in LBs is 
highly phosphorylated at serine (Ser)129 (almost 90% of α-syn), suggesting an important role 
for phosphorylation in α-syn aggregation and LB formation, although it is still debatable its role 
in neurotoxicity. A group of kinases have been suggested to be responsible for α-syn 
phosphorylation. These include polo-like kinases (PLK1 and PLK2), casein kinases (CK-1 and 
CK-2) and leucine-rich repeat kinase 2 (LRRK2). Moreover, previous evidences suggest that 
glial-derived neurotrophic factor (GDNF) may offer potential therapeutic protection in PD. 
Thus, the aim of this study was to evaluate the role of such kinases (through inhibition by 
potential selective compounds) and GDNF in regulating the phosphorylation of α-syn at Ser129 
in cells subjected to Fe, an inducer of oxidative stress. In addition, we evaluated the effects of 
kinase inhibitors, Fe and GDNF on cell toxicity. For this purpose, we used SH-SY5Y human 
neuroblastoma cells conditionally overexpressing wild-type (WT) α-syn in a Tet-Off system 
regulated by doxycycline (Dox). 
Our results demonstrated that α-syn overexpression triggered by the absence of Dox led to 
a decrease in cell viability when compared to cells incubated with Dox, as assessed by Alamar 
Blue assay. This may suggest that an abnormal production of α-syn is toxic. We also showed 
that, with the exception of PLKs inhibitors, nanomolar concentrations of selected kinase 
inhibitors led to an acceptable percentage of viable cells. Moreover, assessment of plasma 
membrane integrity and caspase-3-like activity in cells exposed to the selected inhibitors, as 
well as FeSO4 (Fe, 500µM) and GDNF (20 ng/ml) did not reveal significant cytotoxic effects 
upon the cells, compared with respective control. We also were able to demonstrate that GDNF 
induced the early activation of PI-3K/Akt signaling pathway, as highlighted by increased levels 
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of phosphorylated Akt 10 min after incubation with GDNF. Interestingly, exposure for 2 h with 
Fe or GDNF increased α-syn (Ser129) phosphorylation. However, pre-incubation of GDNF 
prevented Fe-induced α-syn phosphorylation state. This observation may suggest that GDNF is 
important for reducing α-syn phosphorylation induced by oxidative stress. Finally, pre-
incubation of cells with inhibitors of LRRK2 or CK-2 (in particular) followed by Fe exposure 
largely precluded Fe-induced stimulation of α-syn phosphorylation. 
Data presented in this work seem to indicate that CK-2 is among potential kinases involved 
in α-syn phosphorylation at Ser129. Likewise, GDNF seems to be able to counteract increased 
α-syn phosphorylation evoked by Fe, which may largely depend on the activation of 
intracellular PI-3K/Akt signaling pathway. Because α-syn phosphorylation has been shown to 
play an important role in disease pathogenesis, these strategies may represent a promising 
therapeutic solution in PD. 
 
 
 
Key words: Parkinson’s disease, α-synuclein phosphorylation, oxidative stress, kinase 
inhibitors, GDNF. 
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1.1. PARKINSON´S DISEASE - AN OVERVIEW 
1.1.1. Historical milestones 
In 1817 “An Essay of the Shaking Palsy” was the first report in which, his author, James 
Parkinson, described the clinical syndrome that was later to bear his name (Parkinson, 2002). 
He identified six cases, three of whom he personally examined the other three he observed 
on the London streets. Anteriorly referred as ‘‘paralysis agitans’’, Charcot later in the 19th 
century gave credit to Parkinson denominating the disease as ‘‘maladie de Parkinson’’ or 
Parkinson’s disease (PD). Charcot also recognized non-tremulous forms of PD and correctly 
distinguished that slowness of movement should be differentiated from weakness or ‘‘lessened 
muscular power’’, a term originally used by Parkinson (Kempster et al., 2007). More than a 
century passed (1919) after the first reference to the disease by Parkinson before it was 
recognized that patients with PD are characterized by a profound and selective loss of 
nigrostriatal dopaminergic neurons, and 140 years passed (1957) before dopamine was 
discovered as a neurotransmitter by Carlsson and colleagues in Lund, Sweden (Bjorklund and 
Dunnett, 2007). In 1960 Ehringer and Hornykiewicz discovered that dopamine concentrations 
are deeply decreased in the striatum of patients with PD (Hornykiewicz, 2006; Bjorklund and 
Dunnett, 2007) enabling in the following year, the first trials of levodopa (precursor of 
catecholamines) in PD patients (Birkmayer and Hornykiewicz, 1961). The improvement of 
akinesia by the injected levodopa in PD patients was first demonstrated in 1961 and was 
followed by the development of oral levodopa later in the decade (Cotzias at al., 1969; 
Birkmayer and Hornykiewicz, 1998). 
1.1.2. Prevalence 
Alzheimer's disease (AD) is the first most common neurodegenerative disorder followed by 
PD (de Lau and Breteler, 2006). In industrialized countries, the prevalence (percentage in a 
population at a certain moment) of PD is about 0.3% of the entire population. Such a disease is 
more prevalent in the elderly and its incidence gradually rises with age. The prevalence of 1% in 
population over 60 years of age increases to 4% in those over 80 (de Lau and Breteler, 2006). 
Regarding the onset of disease the mean age is about 60 years, however 5-10% of cases, 
designated as young onset, begin between 20 and 50 years of age (Samii et al., 2004). There is 
some controversy regarding the incidence of the disease either in men or in women, some 
studies reported that is more common in men, others however failed to found differences 
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between the sexes. PD incidence per year is 8-18 cases per 100,000 persons (de Lau and 
Breteler, 2006). 
1.1.3. Pathology spreading 
PD is neuropathologically characterized by a progressive and profound loss of 
dopaminergic neurons within the substantia nigra (SN), particularly affecting the ventral region 
of the pars compacta, and by the presence of intracytoplasmic, proteinaceous inclusions termed 
as Lewy bodies (LBs) (Forno et al., 1996). Analysis of post-mortem brains of individuals 
displaying PD, showed a loss of 50–70% of nigral neurons in this region compared to the same 
region in healthy individuals (Marsden, 1990; Lang and Lozano, 1998; Ross et al., 2004; Dauer 
and Przedborski, 2003). 
During the progress of disease, the severity of the neuropathological changes continuously 
increases, occurring a known distribution pattern through which it is possible to predict 
alterations. Even in the brains of individuals, in which there is no clinical evidence for motor 
dysfunctions associated to the disease, this kind of alterations can be developed at some 
extension, and therefore is convenient to subdivide the course of disease into presymptomatic 
and symptomatic phases (Wolters et al. 2000; Del Tredici et al. 2002; Braak et al. 2003).  
 
   
Figure 1.1 - Diagram showing the ascending pathological process (white arrows). Progression of LB 
deposits would initially begin in the medulla oblongata and in the olfactory bulb and progress in a 
caudorostral pattern into neocortex regions. The shading intensity of the colored areas corresponds to the 
severity of the disease. Dark red regions correspond to the initial stages (presymptomatic phase), light red 
regions correspond to the later stages (symptomatic phase). Based on Braak et al., 2004. 
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Some post-mortem studies based on the analysis of Lewy neurites (LNs) and LBs 
accumulation, have shown that some brain structures become damaged prior to SN (Del Tredici 
et al. 2002; Braak et al. 2003). The generation of abnormal inclusion bodies in the brain begins 
at the dorsal motor nucleus of the vagal nerve plus adjoining intermediate reticular zone and the 
olfactory bulb, and spreads out accordingly to a caudorostral predictable pattern, from the lower 
brain stem to the neocortex. The proposed model for PD progression is based on the 
identification of six neuropathological stages (Figure 1.1), each stage is characterized by the 
continual development of LNs in the interior of cellular processes and LBs in the cell bodies of 
the affected neurons (Braak et al., 2004 for review). During the progression of the disease, parts 
of the limbic, autonomic and somatomotor systems become seriously damaged. In the 
presymptomatic phase (stages 1-2), inclusion bodies are restricted to the medulla 
oblongata/pontine tegmentum and olfactory bulb/anterior olfactory nucleus. In the third and 
fourth stages, SN and other components of midbrain and forebrain become the centre of 
pathological alterations. Individuals who achieve this level, probably moves into the 
symptomatic phase of the disease, this corresponds to the onset of the motor symptoms. In the 
final stages 5-6, the neurodegenerative process reaches its greatest topographic extent entering 
in the mature neocortex, and the fullest manifestation of the disease is observed (Braak et al., 
2004 for review), accompanied by neuronal cell loss. 
1.1.4. Clinical features 
There are four main features of PD, grouped under the acronym TRAP: Tremor at rest, 
rigidity, akinesia (or bradykinesia) and postural instability. Moreover, flexed posture and 
freezing (motor blocks) have been included among classic PD features. 
1.1.4.1. Motor features 
The most characteristic clinical feature of PD is bradykinesia or slowness of movement. 
Basal ganglia disorders have bradykinesia as a hallmark, and it encompasses difficulties with 
planning, initiating and executing movement and with performing simultaneous and sequential 
tasks (Berardelli et al., 2001). The initial manifestation is often slowness in performing daily 
tasks and also slowness of movements and reaction times (Cooper et al., 1994; Giovannoni et 
al., 1999).  
Rest tremor is also one of the most common and easily recognized symptoms of PD. 
Tremors are unilateral and almost always are potentiated in the distal part of an extremity. Rest 
tremor in PD patients can also affect the lips, chin, jaw and legs but, unlike essential tremor, 
rarely involves the neck/head or voice. Typically, rest tremor disappears with action and during 
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sleep (Jankovic, 2008 for review). Many lines of evidence indicate that essential tremor is a risk 
factor for PD (Shahed and Jankovic, 2007). Many PD patients, beyond rest tremor also develop 
postural tremor that is more prominent and disabling than rest tremor and may be the first 
manifestation of the disease (Jankovic et al., 1999; Jankovic, 2002).  
One of the most disabling symptoms of PD known as Freezing is a form of akinesia (loss 
of movement) (Giladi et al., 2001). Although freezing is a characteristic feature of PD, it does 
not occur universally (Bloem et al., 2004). Freezing most commonly affects the legs during 
walking, but the arms and eyelids can also be involved (Boghen, 1997). It characteristically 
manifests as a sudden and transient inability to move. This may include hesitation in the 
beginning of walk (start hesitation) or a sudden incapacity to move the feet during specific 
situations (e.g., turning or walking through a narrow passage, crossing busy streets, approaching 
a destination) (Jankovic, 2008 for review). 
Usually accompanied by the “cogwheel” phenomenon, rigidity is characterized by 
increased resistance, particularly when associated with an underlying tremor, present throughout 
the range of passive limb movement (flexion, extension or rotation about a joint). It occurs 
proximally (e.g., neck, shoulders, hips) and distally (e.g., wrists, ankles) (Jankovic, 2008 for 
review). Moreover, neck and trunk rigidity (axial rigidity) may occur, resulting in abnormal 
axial postures (e.g., anterocollis the anterior flexion of the neck and scoliosis an abnormal 
curving of the spine.). Rigidity is often associated with postural deformities resulting in flexed 
neck and trunk posture and flexed elbows and knees (Jankovic, 2008 for review). Other skeletal 
abnormalities comprehend extreme neck flexion (‘‘dropped head’’ or ‘‘bent spine’’) and 
forward truncal flexion (camptocormia) and scoliosis (Askmark et al., 2001; Azher et al., 2005; 
Ashour and Jankovic, 2006; Djaldetti and Melamed, 2006). 
Postural instability is generally a manifestation of the late stages of PD and usually occurs 
after the onset of other clinical features. The increased risk of hip fractures comes from postural 
instability (along with freezing of gait) that is the most common cause of falls (Williams et al., 
2006).  
PD patients may exhibit a number of secondary motor symptoms that may have impact on 
their functioning at home, at work and while driving (Singh et al., 2007). In some cases, 
voluntary movements are accompanied by unintended movements in homologous muscles on 
the opposite side of the body. These so-called mirror movements may be observed in early 
asymmetric PD (Li et al., 2007). Speech disorders in patients with PD, referred to as ‘‘tip-of-
the-tongue phenomenon’’, are characterized by monotonous, soft and breathy speech with 
variable rate and frequent word finding difficulties (Critchley, 1981; Matison et al., 1982). 
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Respiratory abnormalities in patients with PD was also reported and can be restrictive or 
obstructive (Sabate et al., 1996).  
1.1.4.2. Non-motor features 
Non-motor symptoms are a common and depreciated feature of PD (Zesiewicz et al., 
2006). These include autonomic dysfunction, cognitive/neurobehavioral disorders, sleep and 
sensory abnormalities. The clinical manifestation of non-motor symptoms and the subjacent 
mechanisms involving non-dopaminergic nerve cells are still intensively discussed. Affected 
non-dopaminergic nerve cells embrace monoaminergic cells in the raphe nuclei, cholinergic 
cells in the nucleus basalis of Meynert (related with cognitive deficits) (Hilker et al., 2005), the 
monoaminergic cells in the locus coeruleus (Zarow et al., 2003), pedunculopontine tegmental 
nucleus (probably associated to gait problems) (Rinne et al., 2008), and hypocretin cells in the 
hypothalamus (which may be related to the sleep disorders) (Thannickal et al., 2007). About 30-
50% of these nondopaminergic neurons are lost in the final-stage of PD (Obeso et al., 2010). 
1.1.5. Familial and sporadic forms 
PD cases have been divided in two forms: familial and sporadic. The sporadic form is the 
most common and represents 90-95% of total cases. The familial/inherited form covers the 
remaining 5-10% of PD cases and is caused by mutations on identified critical genes (Dauer and 
Przedborski, 2003). Both sporadic and inherited forms of PD share the degeneration of 
dopaminergic neurons in the substantia nigra pars compacta (SNpc), which accumulate 
misfolded and aggregated α-synuclein (α-syn) (Spillantini et al., 1997). 
Identification of genes involved in familial forms of PD, provided great advances in 
understanding the molecular mechanisms underlying the disease pathology, and allowed the 
first identification of a definitive cause for the disease (Jain et al., 2005). Among the most 
studied genes associated with familial PD, there are two autosomal-dominant genes, α-syn and 
leucine-rich repeat kinase 2 (LRRK2) and three autosomal-recessive genes parkin, phosphatase 
and tensin (PTEN) homolog-induced putative kinase 1 (PINK1) and DJ-1 (Jain et al., 2005). 
Concerning sporadic PD, some efforts were made in order to find its causes and several 
hypotheses have been proposed including, mitochondrial dysfunction, oxidative stress, 
proteasomal dysfunction and pesticides. Many of these causes are also associated with familial 
form of PD, and is not well understood whether they are the cause or consequence of the 
disease. Lewy bodies are composed of α-syn modified by oxidation, resulting in an increased 
capacity of this protein to misfold and aggregate (Giasson et al., 2000). The link between 
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misfolded α-syn and oxidative stress is shrouded in controversy, however, oxidative stress has 
been shown to lead to α-syn aggregation, thus it may contribute to sporadic PD (Zhou et al., 
2004). Rotenone, maneb, and paraquat (pesticides and herbicide, respectively) may also have a 
role in sporadic PD as well. Rotenone and paraquat inhibit mitochondrial complex I (Sherer et 
al., 2003; Yang et al., 2007) and maneb preferentially inhibits mitochondrial complex III 
(Cicchetti et al., 2009).  These agents have been reported to induce specific symptoms when 
administered to mice (Uversky et al., 2004). Furthermore, mitochondrial dysfunction may also 
contribute to sporadic PD since rotenone, paraquat, and MPTP (1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine) inhibition of mitochondrial complex I, lead to cell damage (Abou- Sleiman 
et al., 2006) and increased degeneration of dopaminergic neurons (Mizuno et al., 1989; Kweon 
et al., 2004). 
1.2. PARKINSON´S DISEASE PATHOGENESIS 
1.2.1. Pathogenic mutations 
Although PD was mostly considered a sporadic rather than a genetic disorder, genetic 
analysis of PD families, demonstrated that approximately 5-10% of individuals with clinical 
manifestations have an evident genetic-related cause, showing a classical dominant or recessive 
mode of inheritance in accordance with Mendelian laws. Over the last 10 years, were identified 
15 genetic loci for PD and 11 genes (Table 1.1) for PARK loci, this includes PARK1 and 
PARK4/α-syn, PARK2/parkin, PARK5/ubiquitin carboxyl-terminal esterase L1 (UCHL1), 
PARK6/PINK1, PARK7/DJ-1, PARK8/LRRK2, PARK9/ATPase type 13A2 (ATP13A2), 
PARK11/Grb10 interacting GYF protein 2(GIGYF2), PARK13/Htr serine peptidase 2 
(HTRA2/OMI), PARK14/phospholipase A2, group VI (PLA2G6) and PARK15/F-box protein 7 
(FBXO7) (Lesage and Brice, 2009; Hatano et al., 2009 for review). From all of these proteins, 
the most well studied and more frequently associated to the disease will be further described, 
namely α-syn, parkin, DJ-1, PINK1 and LRRK2. 
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Table 1.1 - Summary of genes associated with PD 
PARK loci Map position Gene Forms of PD Functions Mutations Onset 
PD-associated loci and genes with conclusive relevance 
PARK1/4 4q21-q23 SNCA 
EOPD AD and 
sporadic 
Membrane 
trafficking 
A30P, E46K, A53T, 
Genomic 
duplications/triplications 
~40 
PARK8 12q12 LRRK2 
LOPD AD and 
sporadic 
Membrane 
trafficking, 
Kinase 
>40 missense variants, >7 
of them pathogenic, 
including the common 
G2019S 
~65 
PARK2 6q25.2-q27 Parkin 
Juvenile and 
EOPD AR and 
sporadic 
UPS, E3-ligase 
>100 mutations (point 
mutations, exonic 
rearrangements) 
<40 
PARK6 1p35-p36 PINK 1 ARPD 
Mitochondria, 
kinase 
>40 point mutations, rare 
large deletions 
32 ± 7 
PARK7 1p36 DJ-1 EOPD AR Oxidative stress 
>10 point mutations and 
large deletions 
27–40 
PARK9 1p36 ATP13A2 
Juvenile AR 
Kufor–Rakeb 
syndrome and 
EOPD 
Lysosome? 
Autophagy? 
>5 point mutations 11–16 
PD-associated loci and genes with unknown evidence 
PARK3 2p13 Unknown LOPD AD  Not identified 35–89 
PARK5 4p14 UCHL 1 LOPD AD 
UPS, Ubiquitin 
hydrolase 
One mutation in a single 
PD sibling pair 
~50 
PARK10 1p32 Unknown Unclear  Not identified ~65 
PARK11? 2q36-q37 GIGYF2 LOPD AD IGF-1 signaling Seven missense variants Late 
PARK13 2p13 
Omi/ 
HTRA2 
Unclear 
Mitochondria, 
protease 
Two missense variants Late 
PARK14? 22q13.1 PLA2G6 
Juvenile AR 
levodopa-
responsive 
dystonia-
parkinsonism 
Phospholipase 
enzyme 
Two missense mutations 20–25 
PARK15? 22q11-q13 FBXO7 
EO AR 
parkinsonian-
pyramidal 
syndrome 
UPS, E3-ligase Three point mutations 10–19 
PARK12 Xq21-q25 Unknown Unclear  Not identified Late 
 
EO, early-onset; LO, late-onset; AD, autosomal dominant; AR, autosomal recessive; PD, Parkinson’s 
disease; SNCA, α-Syn; UPS, ubiquitin-proteasome system. Based on Lesage and Brice, 2009 and Hatano 
et al., 2009 for review. 
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1.2.1.1. α-Synuclein 
α-Syn is a natively unfolded presynaptic protein believed to play a role in synaptic vesicle 
recycling, storage and compartmentalization of neurotransmitters that associates with vesicular 
and membranous structures (Abeliovich et al., 2000; Yavich et al., 2004; Yavich et al., 2006). 
Structurally, α-syn consists of an N-terminal amphipathic region, an acidic C-terminal domain 
and a hydrophobic middle region (containing the non-amyloid-β component domain, NAC). 
Three missense mutations (Figure 1.2) in α-syn gene (A53T, A30P and E46K) (Polymeropoulos 
et al., 1997; Kruger et al., 1998; Zarranz et al., 2004) were identified as a cause for autosomal 
dominant PD.Furthermore, genomic duplications/triplications in the same gene were also 
associated with autosomal dominant PD (Singleton et al., 2003), leading to a pathogenic 
overexpression of the wild-type protein, however, single nucleotide polymorphisms in the 
SNCA promoter have been described to be related with sporadic PD (Edwards et al., 2010).  
 
 
Figure 1.2 - Schematic representation of α-syn structure and domains. Missense mutations genetically 
linked to Familial PD are represented. Based on Greggio et al., 2011. 
 
α-Syn has a high propensity to aggregate due to its hydrophobic NAC domain. α-Syn 
fibrils constitute the major structural component of LBs and suggest a role for aggregated α-syn 
in PD pathogenesis (Spillantini et al., 1998). Several recent studies provide evidences for the 
NAC domain and the truncated forms of α-syn in mediating neurodegeneration in vivo. 
Overexpression of truncated α-syn lacking residues 71–82 (within NAC domain) failed to 
aggregate and form oligomeric species in flies, leading to an absence of dopaminergic pathology 
(Periquet et al., 2007). On the other hand, expression of truncated α-syn, containing the NAC 
domain induced increased aggregation into large inclusion bodies, accumulation of high 
molecular weight α-syn species and enhanced dopaminergic neurotoxicity in flies (Periquet et 
al., 2007). Another study that supports these observations, refers progressive loss of nigral 
dopaminergic neurons with pathological inclusions and associated behaviours in mice 
expressing C-terminal truncated human α-syn (containing residues 1-120), on mouse α-syn null 
background, suggesting a critical role for C-terminal truncated α-syn in aggregation and 
dopaminergic toxicity in vivo (Tofaris et al., 2006). This suggests that alpha-syn C-terminal 
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region may be an important regulator of its aggregation in vivo and pathogenic α-syn mutations 
may enhance C-terminal truncation-induced aggregation (Li et al., 2005). 
Currently, it is not clear whether accumulation of misfolded proteins that lead to LB-like α-
syn aggregates formation is toxic or protective in PD. Pharmacological strategies known to 
promote inclusion formation seem to protect against α-syn toxicity (Bodner et al., 2006). A 
recent study using a protein aggregate filtration assay demonstrated that synaptic pathology and 
neurodegeneration occurs due to abundant α-syn associated with presynaptic terminals, in 
contrast to α-syn aggregates from LBs in postmortem brains from patients with Lewy body 
dementia (LBD), supporting the idea that LBs play a less important role in toxicity (Kramer and 
Schulz-Schaeffer, 2007). However it has shown that α-syn can misfold and subsequently 
aggregate and the resultant aggregates are neurotoxic (Fink, 2006). 
The mechanisms by which abnormal processing and accumulation of α-syn impair basic 
cellular functions leading to dopaminergic neurodegeneration have been intensely studied. One 
of the earliest defects following α-syn accumulation in vivo is the disruption of the trafficking 
between endoplasmic reticulum (ER) and Golgi apparatus, causing ER stress (Cooper et al., 
2006). Furthermore, mitochondrial pathology was previously observed in transgenic mice 
expressing human A53T α-syn (Martin et al., 2006; Stichel et al., 2007), providing a crucial role 
for α-syn in modulating mitochondrial function in neurodegeneration. This can result from the 
fact that α-syn may also be a modulator of oxidative damage, since mice lacking α-syn were 
shown to be resistant to mitochondrial toxins (Williams et al., 2006). Moreover, in human α-syn 
transgenic mice, nigral dopaminergic neurons were reported to be vulnerable to degeneration 
and mitochondrial dysfunction following parkinsonian neurotoxin MPTP (Klivenyi et al., 2006; 
Nieto et al., 2006). In addition, β-synuclein (β-syn) seems to protect α-syn-induced toxicity by 
reducing its expression (Song et al., 2004), through blockade of pore-like α-syn oligomers 
development (Fan et al., 2006). Furthermore, overexpression of mutant α-syn (A53T and A30P) 
increased cytoplasmic catecholamine concentrations, leading to the disruption of pH and normal 
vesicular function and facilitated the toxicity of oxidized catechol metabolites, resulting in 
selective degeneration (Mosharov et al., 2006; Tsigelny et al., 2007). α-Syn and its biochemical 
abnormalities have been shown to activate stress-signaling protein kinases (Hasegawa et al., 
2006), affect age-related decrease in neurogenesis (Klegeris et al., 2008), impair microtubule-
dependent trafficking (Winner et al., 2007), reduce intercellular communications at gap 
junctions (Lee et al., 2006), inhibit histone acetylation in the nucleus to promote toxicity (Sung 
et al., 2007), regulate  dopamine  homeostasis through regulation of  dopamine transporter 
activity (Kontopoulos et al., 2006), regulate tyrosine hydroxylase (TH) activity (Giovannoni et 
al., 1999), or vesicle formation (Wersingerand and Sidhu, 2003). α-Syn has also been 
implicated in ER-Golgi trafficking (Peng et al., 2005), interaction with mitochondrial proteins 
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(Lotharius et al., 2002), and control of nuclear transcription (Cooper et al., 2006, Martin et al., 
2006). These pathophysiological aspects are detrimental to normal functioning of dopaminergic 
neurons and provide implications for disease pathogenesis in α-syn-induced PD (Kontopoulos et 
al., 2006). 
1.2.1.1.1. Spreading of α-syn aggregates 
Induction and spread of protein aggregates in PD brains has been a topic of intense 
research over the last years. The transmission of α-syn to healthy unaffected neurons from 
pathologically affected neurons may be a crucial step in the anatomical spread of the disease 
through the brain. Some evidences suggested a pathological propagation mechanism, identical 
to that observed in prion diseases (Angot et al., 2010). 
In the past decades, neural grafts in the striatal region have been reported to carry out a 
long-term relief of some PD motor symptoms. Recently, α-syn-positive LBs and LNs were 
observed in grafted neurons in post-morten brains of PD patients who received transplants of 
embryonic mesencephalic tissue more than 10 years prior to death (Kordower et al., 2008; Li et 
al., 2008; Li et al., 2010). These observations were in accordance with the hypothesis postulated 
by Braak and colleagues which states that a neurotropic pathogen may cause the propagation of 
LB and LN pathology from a peripheral origin (olfactory bulb, intestine) to the brainstem and 
subsequently up to neocortical regions during PD progression (Braak et al., 2003). α-Syn could 
then be considered as a pathogen that disseminates from neuron to neuron, contributing to the 
neuropathological progression in PD and to the LB profile in grafted embryonic nerve cells 
(Hansen et al., 2011). It is not completely understood how these embryonic transplanted 
neurons acquired such pathologies. A possible explanation concerning the emergence of 
pathology in the grafted neurons is the transference of α-syn from the host nerve cells to the 
grafted cells, with the subsequent seeding-like process of α-syn aggregation in recipient cells, 
similar to the mechanisms underlying the prion diseases (Angot et al., 2010). α-Syn was 
predominantly considered a cytoplasmic protein. However, α-syn has also been observed in 
human cerebrospinal fluid and plasma of both PD and normal individuals (Borghi et al., 2000; 
El-Agnaf et al., 2003). It was recently demonstrated in mice that neurons expressing α-syn were 
able to transfer this protein to neurons grafted into the striatum, in analogy to the mechanism 
observed in the grafted neurons in PD patients (Hansen et al., 2011). In vitro experiences of co-
culturing involving α-syn over-expressing cells with non-expressing cells and neuronal 
precursor cells have also demonstrated the transference of α-syn, according to paradigm of cell-
to-cell transmission (Desplats et al., 2009). In both cultures of human and rodent cells, it was 
observed α-syn transmission and the subsequent seed aggregation of endogenous α-syn in the 
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recipient cells (Danzer et al., 2009; Luk et al., 2009; Nonaka et al., 2010; Waxman and Giasson, 
2010; Hansen et al., 2011; Volpicelli-Daley et al., 2011) Several years ago, it was shown that a 
small but significant amount of this protein and its aggregates were secreted from neurons via 
exocytosis (Lee et al., 2005). Furthermore, cultured neurons were capable to internalize external 
α-syn aggregates via endocytosis (Lee et al., 2008a; Lee et al., 2008b). In addition, a recent 
study described the association between α-syn secretion and vesicle membranes, whose 
composition and biophysical properties were coincident with those in exosomes (Figure 1.3) 
(Emmanouilidou et al., 2010).  
 
 
Figure 1.3 - Proposed mechanisms for cell-to-cell transmission of misfolded proteins. (A) Exocytosis and 
endocytosis. Misfolded proteins can be stored into exocytotic vesicles (top left arrows), which fuse with 
the cell membrane and release proteins into the extracellular space. Once in the extracellular medium, 
misfolded proteins can be taken up by cells via lipid raft-mediated endocytosis (bottom left; zigzags 
represent lipid rafts), or more likely by receptor-mediated endocytosis (bottom right; half rectangle with 
oval indentation represents receptor). (B) Another mechanism for cell-to-cell transfer of misfolded 
proteins is within exosomes, small membrane-bound vesicles (green circles) that can form within 
multivesicular bodies (orange circle), which are released and endocytosed by a surrounding cell (right; 
arrows). Based on Garden and La Spada, 2012. 
 
In other recent studies, acceleration of α-syn aggregate formation in the brain of young, 
presymptomatic transgenic mice, along with earlier onset of neurological symptoms, have been 
described after intracerebral insertion of brain tissue from old transgenic mice with 
synucleinopathy (Mougenot et al., 2012; Luk et al., 2012). The same effects were observed after 
inoculation of recombinant α-syn fibrils directly into the brain of young, transgenic mice (Luk et 
al., 2012). A very recent study has demonstrated for the first time in vivo the sequence of events 
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underlying the prion-like hypothesis, i.e. the transmission of α-syn from a donor to a recipient 
neuron, followed by the seeding and aggregation of endogenous α-syn in the recipient neuron 
around a core of transferred α-syn. In the same study it was shown that transferred α-syn co-
localized with a marker for early endossomes in grafted nerve cells (Angot et al., 2012). These 
studies reinforce the idea of a direct α-syn transmission from pathologically affected to healthy 
neurons leading to the disease progression through the nervous system. 
1.2.1.2. LRRK2 
Mutations in LRRK2 or dardarin cause autosomal dominant PD (Deng et al., 2005; Petit et 
al., 2005). LRRK2 gene encodes a 2527 amino acid multidomain, 280 kDa protein (Figure 1.4), 
which belongs to ROCO protein family that includes two characteristic domains: a Ras of 
complex protein (Roc) Rho/Ras-like-GTPase domain and a carboxy-terminal of Roc (COR) 
domain. Therefore, the ROCO family can be defined as the group of proteins containing the Roc 
and COR domains. LRRK2 includes also a protein kinase domain of the mitogen-activated 
protein kinase kinase kinase (MAPKKK) family, as well as a WD40-repeat and leucine-rich 
repeat domains (Marín et al., 2008). The occurrence of mutations in several distinct domains, as 
well as deletions or truncations in LRRK2 gene, suggest a gain-of-function mechanism, 
associated with dominant inheritance. The physiological role of LRRK2 is unknown but the 
existence of multiple functional domains indicates an involvement in a variety of cellular 
functions. This protein is expressed in the majority of forebrain structures, including 
nigrostriatal dopaminergic neurons and is predominantly a cytoplasmic protein, mainly 
localized in the Golgi apparatus, synaptic vesicles, plasma membrane, lysosomes, but also 
associates with the outer mitochondrial membrane (Zimprich et al., 2004; Muqit et al., 2006; 
Tang et al., 2006; Wang et al., 2006; Murakami et al., 2007).  
 
 
Figure 1.4 - Schematic representation of LRRK2 structure and domains. Point mutations are represented 
in different domains. Based on Greggio et al., 2011. 
 
Point mutations have been identified in almost all domains of LRRK2 gene, such as 
R1441C, R1441G in the Roc domain, Y1699C in the COR domain, and G2019S and I2020T in 
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the kinase domain (Kondo et al., 2011). Overexpressed mutant LRRK2 showed to be toxic  in 
cultured cells (Cookson et al., 2007; Sakamoto et al., 2009) and Drosophila, (Greggio et al., 
2006; Cookson, 2010), however loss of neurons was not observed in transgenic mice 
overexpressing R1441G and R1441C mutants (Smith et al., 2006; Imai et al., 2008). LRRK2 
mutations have been related to clinically typical PD features, ranging from nigral degeneration 
without LBs, to nigral degeneration with widespread LBs or neurofibrillary tangles (Liu et al., 
2008). 
Due to its interaction with Rab5a, LRRK2 interferes with vesicle endocytosis (Wang et al., 
2008), plays a role in activation of apoptosis through interaction with death adaptor Fas-
associated protein with death domain (FADD) (Parisiadou et al., 2009), participates in the 
control of protein translation through phosphorylation of 4E-BP1 (Shin et al., 2008) and 
interacts with the microRNA pathway to regulate protein synthesis (Sakaguchi-Nakashima et 
al., 2007). Several groups also reported that LRRK2 interacts with alpha and beta tubulins, 
(Imai et al., 2008; Ho et al., 2009; Gehrke et al., 2010), suggesting that LRRK2 may play a role 
in cytoskeleton dynamics. Deletion mutants of LRK-1, a LRRK2 homolog protein in 
Caenorhabditis elegans, led to the depletion of synaptic vesicle proteins in dendritic endings of 
neurons, defining a possible role in polarized sorting of synaptic vesicle proteins (Paisan-Ruiz et 
al., 2004). Some studies demonstrated the capacity of LRRK2 to associate with lipid rafts, 
localize to LBs and regulate neurite length and branching (Biskup et al., 2006; Galter et al., 
2006; Higashi et al., 2007). These findings suggest that LRRK2 modulates synaptic vesicle 
recycling, neurite outgrowth and operates in an inherent manner to Golgi, lysosomes and 
mitochondria, which dysfunction may compromise dopaminergic neuron survival (Taymans et 
al., 2006). It is also evident from several studies that altered LRRK2 kinase activity due to 
disease-causing mutations affected cell viability through apoptosis, imputing a direct role of 
pathological activation of LRRK2 kinase causing neurodegeneration (MacLeod et al., 2006; 
Simon-Sanchez et al., 2006; Zhu et al., 2006; Hatano et al., 2007; Sakaguchi-Nakashima et al., 
2007).  
1.2.1.3. PARKIN 
The parkin protein is constituted by a 465 amino acid sequence, containing an N-terminal 
ubiquitin like domain, a central linker region and a C-terminal RING (Really Interesting New 
Gene) domain consisting of two RING finger motifs separated by an in between RING domain. 
Parkin acts as an E3 ubiquitin protein ligase by targeting abnormal proteins to the ubiquitn 
proteasome system for degradation. Mutations in this protein are described to cause the loss of 
its E3 ligase activity and lead to autosomal recessive early-onset PD (Zhang et al., 2000; Iwata 
et al., 2001; Thomas and Beal, 2007). Several parkin substrates have been identified and the 
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accumulation of one or several of these substrates was shown to be implicated in 
neurodegeneration (Shimura et al., 2000). Indeed, Kitada and colleagues (1998) reported that 
when dopaminergic neurons were subjected to a variety of toxic insults, parkin increased 
neuronal survival (Kitada et al., 1998). Parkin appears to have a neuroprotective role through 
activation of IkappaB kinase/nuclear factor-kappaB signaling, since parkin mutants failed to 
stimulate this pathway (Dawson, 2006). Furthermore, the ubiquitin-like (UBL) domain of 
parkin connects with ubiquitin interacting motifs (UIM) of Eps15 [an adaptor protein involved 
in epidermal growth factor receptor (EGFR) endocytosis and trafficking] and ubiquitinates the 
substrates in a proteasome-independent manner. Parkin impairs the binding between Eps15 
UIMs and ubiquitinated EGFR delaying EGFR internalization and degradation, promoting 
phosphatidylinositol 3-kinase/Akt cell survival signaling (Feany and Pallanck, 2003). Parkin 
also seems to have a role in modulation of key mitochondrial functions, including a role in 
mitochondrial morphogenesis during spermiogenesis, the final stage of spermatogenesis (Henn 
et al., 2007), and the enhancement of mitochondrial biogenesis in proliferating cells through 
transcription and replication of mitochondrial DNA (Fallon et al., 2006). In cases of inactivation 
of the putative mitochondrial serine/threonine kinase (PINK1), that causes autosomal recessive 
PD, parkin was shown to rescue mitochondrial dysfunction, muscle degeneration and 
dopaminergic loss in flies (Clark et al., 2006; Kuroda et al., 2006; Yang et al., 2006; Riparbelli 
and Callaini, 2007). In addition, a study from Stichel and collaborators (2007) demonstrated that 
α-syn-induced mitochondrial dysfunction was further enhanced due to lack of parkin activity in 
vivo, implicating a crucial role of this protein in modulating mitochondrial function in α-syn-
induced PD (Stichel et al., 2007). Post-translational modifications of parkin either due to 
oxidative or nitrative stress also compromise its protective function by impairing the E3 ligase 
activity (Casarejos et al., 2006; Park et al., 2006). Some studies also provided important insights 
on the role of mutant parkin in vivo. Expression of mutant human parkin in flies (but not the 
wild-type (WT) protein), led to an age-dependent dopaminergic neurodegeneration 
accompanied by motor impairment, implying a toxic gain of function mechanism (La Voie et 
al., 2005). This is in contrast with the lack of nigral dopaminergic degeneration in mouse 
models generated by targeted deletion of parkin, causing a loss of function phenomenon (Chung 
et al., 2004). Surprisingly, catecholaminergic neurons from parkin knockout mice failed to show 
increased susceptibility to neurodegeneration against neurotoxins (Moore et al., 2005; Sang et 
al., 2007) and human α-syn-induced disease (Chung et al., 2004; Stichel et al., 2007). Although 
parkin may be considered as a neuroprotective agent, these considerations suggest that its 
neuroprotective efficiency is quite selective. Finding the specific neuroprotective pathways that 
are affected due to parkin deficiency will help to identify its role in PD pathogenesis 
(Kontopoulos et al., 2006). 
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1.2.1.4. DJ-1 
Loss -of-function mutations in the DJ-1 locus are related with rare forms of autosomal 
recessive early-onset parkinsonism (Moore et al., 2005a). DJ-1 is a highly conserved protein of 
189 amino acids that belongs to the DJ-1/Thi/PfpI protein super family. It has ubiquitous 
expression in a variety of mammalian tissues, including brain and is localized in cytosol, 
mitochondria and nucleus (Perez et al., 2005; Thomas et al., 2007). Association of DJ-1 
pathogenic mutations to familial PD has helped to identify some of its functions that shed light 
in disease pathogenesis. These include antioxidant, transcriptional co-activation and chaperone 
activity. 
Many lines of evidence suggest that DJ-1 acts as an antioxidant protein (von Coelln et al., 
2006). Due to its inherent ability to undergo self-oxidation and eliminate hydrogen peroxide 
(H2O2), it was suggested that it may function as a scavenger of other reactive oxygen species 
(ROS) (Solano et al., 2006). Overexpression of WT DJ-1 either in cell culture or dopaminergic 
neurons in vivo protected against a wide variety of toxic injury induced by oxidative stress 
(Bonifati et al., 2003; Bandopadhyay et al., 2004; Thomas and Beal, 2007). This antioxidant 
capacity appears to be related to the stabilization of the antioxidant transcriptional regulator 
Nrf2 (nuclear factor erythroid 2-related factor) by DJ-1, thus preventing association with its 
inhibitor, Keap1 (Kelch-like ECH-associated protein 1) and Nrf2 ubiquitination (Zhang et al., 
2005). This is in accordance with the ability of DJ-1 to increase cellular glutathione levels by 
activating glutamate-cysteine ligase (GCL) (Canet-Aviles et al., 2004). α-Syn aggregation and 
subsequent cell death were described to be inhibited by DJ-1 redox-dependent chaperone 
activity (Taira et al., 2004). Moreover, DJ-1 associates with parkin during oxidative stress 
suggesting a common neuroprotective role (Paterna et al., 2007).  
DJ-1 familial PD-linked mutations have been considered to cause nigral neuron 
degeneration through a loss-of-function mechanism. Furthermore, methionine oxidized DJ-1 
was identified in sporadic PD brains in mass spectrometric studies, suggesting a role for 
methionine oxidation in disease pathogenesis (Inden et al., 2006). Mouse models lacking DJ-1 
developed age-dependent motor deficits, hypokinesia and dopaminergic dysfunction without 
neuronal loss (Zhou and Freed, 2005; Clements et al., 2006). In these mice, the nigrostriatal 
dopaminergic neurons showed an increased susceptibility to the parkinsonian neurotoxin MPTP 
via an unknown mechanism (Shendelman et al., 2004). Increased vulnerability of DJ-1 
knockout mice could be related with increased p53 (protein 53) and Bax (Bcl-2-associated X 
protein) expression (Zhou et al., 2006), deficits in phase II detoxification enzyme NQO1 
(NADPH quinone oxidoreductase 1) (Zhang et al., 2005), irreversible changes in membrane 
potential due to impaired Na
+
/K
+
 ATPase (Moore et al., 2005b), defective phosphatidylinositol 
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3-kinase/Akt signaling (Choi et al., 2006) and incapacity of Daxx (Death domain-associated 
protein 6) protein to inhibit ASK1- (apoptosis signal regulating kinase 1) induced cell death 
(Goldberg et al., 2005). Concerning dopaminergic neuronal function, it is important to consider 
the ability of DJ-1 to transcriptionally upregulate TH expression by suppressing the sumoylation 
of pyrimidine tract-binding protein-associated splicing factor (Chen et al., 2005). 
1.2.1.5. PINK1 
Mutations in the PINK1 gene were identified to cause early-onset familial PD (Kim et al., 
2005). PINK1 gene encodes a 581 amino acid protein that contains an N-terminal mitochondrial 
targeting sequence and a highly conserved protein kinase domain similar to serine/threonine 
kinases of the Ca
2+
 calmodulin family. It has an expression pattern that suggests mitochondrial 
localization (Bretaud et al., 2007). Little is known about the precise function of PINK1 in the 
pathogenesis of PD. However, its mitochondrial localization, the presence of a kinase domain 
where the majority of mutations occur, indicate a role in mitochondrial dysfunction, protein 
stability and kinase pathways (Yang et al., 2005; Pisani et al., 2006). Truncation of PINK1 C-
terminal and disease-related mutations seem to downregulate its serine/threonine kinase activity 
and confer different autophosphorylation patterns, suggesting an important involvement of its 
kinase activity in mitochondrial function (Junn et al., 2005; Zhong et al., 2006).  
In vitro studies suggest that overexpression of WT PINK1 can prevent staurosporine-
induced cell death, mitochondrial cytochrome c release and subsequent caspase 3 activation 
leading to apoptosis (Gandhi et al., 2006). This is consistent with increased vulnerability of 
neuroblastoma SH-SY5Y cells to the mitochondrial complex I inhibitor rotenone and MPP
+
 (1-
methyl-4-phenyl pyridinium ion) following suppression of PINK1 function by small 
interference RNA (Leutenegger et al., 2006), or expression of PINK1 mutants (Beilina et al., 
2005). Proteasomal stress impaired PINK1 function by mechanisms that lead the protein to 
undergo altered cleavage (Silvestri et al., 2005), an abnormal event that may enable this protein 
to be accumulated in LBs (Yang et al., 2005, Sim et al., 2006). In vivo studies in flies showed 
that PINK1 loss of function either due to expression of disease-causing mutations or due to its 
inactivation by siRNA results in muscle and dopaminergic neuron degeneration as a 
consequence of mitochondrial dysfunction. Interestingly, this degenerative phenotype was 
rescued by overexpression of parkin, revealing the importance of both parkin and PINK1 in 
regulating mitochondrial physiology and survival in flies (Clark et al., 2006; Kuroda et al., 
2006; Yang et al., 2006; Riparbelli and Callaini, 2007). In addition, experiments in flies showed 
that overexpression of human superoxide dismutase 1 (SOD1 or Cu/Zn-SOD) prevented the loss 
of dopaminergic neurons due to PINK1 inactivation, suggesting that the oxidative damage 
pathways are modulated by mitochondrial dysfunction (Scheele et al., 2007). These findings 
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were supported by the fact that oxidative damage induced by PINK1 dysfunction recruited the 
antioxidant DJ-1, maintaining the steady-state levels of PINK1 through a physical interaction 
between these proteins (Beilina et al., 2005). 
PINK1 and parkin have a common signaling pathway and further reports suggested their 
direct interaction (Shiba et al., 2009; Sha et al., 2010), giving rise to the hypothesis that parkin 
is not only recruited for the cytosolic ubiquitination process, but is also involved in 
mitochondria homeostasis. The discovery of parkin translocation from cytosol to depolarized 
mitochondria and subsequent promotion of their degradation by the autophagy-lysosome 
pathway (also known as mitophagy) contributed to support this notion (Narendra et al., 2008). 
This is an intriguing possibility, since parkin has been described as a cytosolic protein (Darios et 
al., 2003; Narendra et al., 2008). On the other hand, it was demonstrated that PINK1 is a 
transmembrane protein located in the outer mitochondrial membrane, with its kinase domain 
facing the cytosol (Zhou et al., 2008). These details related with PINK1 localization and 
topology can be relevant to the reported genetic interaction between parkin and PINK1 since the 
former and the functional domain of the latter are in the same subcellular compartment. 
Subsequently, it has been proved that the recruitment of parkin to depolarized mitochondria is a 
PINK1-dependent process in mammals (Geisher et al., 2010; Vives-Bauza et al., 2010) and 
Drosophila cells (Ziviani et al., 2010). 
Increased oxidative stress or mitochondrial activity impairment are indicated as 
consequences of PINK1 absence or a deficiency in protein activity. Indeed, a report in which 
PINK1 was silenced in the human neuroblastoma SH-SY5Y cell line resulted in oxidative stress 
and mitochondrial dysfunction, which increases over the time (Gegg et al., 2009). PINK1 
deficiency in differentiated neurons also resulted in increased oxidative stress along with a 
substantial enhancement in mitochondrial mass, after the silencing process (Wood-Kaczmar et 
al., 2008). Furthermore, in PINK1 knockout mouse models, it was reported a progressive 
increase in oxidative stress, accumulation of abnormal mitochondrial morphology and inhibition 
of mitochondrial respiration (Gautier et al., 2008; Gispert et al., 2009). A recent study proposed 
a physiological scenario in which PINK1 is needed to recruit parkin to the mitochondria 
afterwards dysfunctional mitochondria are delivered to the perinuclear area, once there they are 
degraded by autophagy (Vives-Bauza et al., 2010). Impairment in the turnover of dysfunctional 
mitochondria, due to mutations in either parkin or PINK1could results in neurodegeneration in 
familial forms of PD (Vives-Bauza et al., 2010). 
At this point of knowledge it is premature to infer about the physiological function of 
PINK1 through its direct interaction with parkin and DJ-1. However, this interaction suggests 
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the involvement of three different proteins causing familial PD in sharing common pathways for 
PD pathogenesis. 
1.2.2. Mitochondrial dysfunction and oxidative damage in PD 
Multiple evidences suggest a pathogenic role for oxidative damage and mitochondrial 
dysfunction in PD. Deficits in the subunits and activity of mitochondrial complex I in blood 
platelets and SNpc of PD patients have been consistently described (Li and Beal, 2005; Greggio 
et al., 2006). Reduction of complex I activity was also observed in cytoplasmic hybrid (cybrid) 
cell lines containing mitochondrial DNA (mtDNA) from parkinsonian patients (Smith et al., 
2006). Epidemiological studies indicate that exposure to industrial wastes, pesticides and 
environmental toxins are also involved in sporadic PD pathogenesis (West et al., 2007). A 
paradigmatic example is the inadvertent discovery that MPTP induced parkinsonism in 
designer-drug abusers. Indeed, MPP
+
 is the toxic metabolite of MPTP, which is selectively 
taken up by dopaminergic neurons, causing mitochondrial dysfunction (Smith et al., 2005a). 
Like MPTP, complex I inhibitors such as rotenone and paraquat induced dopaminergic 
degeneration in rodents, suggesting a pivotal role of mitochondrial dysfunction in PD 
pathogenesis (Iaccarino et al., 2006; Keeney et al., 2006). Multiple lines of evidence support the 
notion of mitochondrial dysfunction in triggering PD (Beal, 2005). Some findings demonstrate 
that neurons of the SNpc have high amounts of mtDNA deletions in postmortem brains from PD 
patients when compared with other neuronal populations in brain- and age-matched controls 
(Swerdlow et al., 1996). A related study revealed that nigral dopaminergic neurons from PD 
patients contained higher levels of clonally expanded somatic deletions in mtDNA, leading to 
mitochondrial dysfunction (Gorell et al., 1998). These results are supported by a study where 
targeted deletion of mitochondrial transcription factor A (TFAM) in midbrain dopaminergic 
neurons led to progressive PD in mice, due to deficiencies in mitochondrial respiratory chain 
and reduced expression of mtDNA (Langston et al., 1983). Moreover, an unexpected low 
mitochondrial mass observed in SNpc of mice might be a contributing factor to vulnerability of 
these selective neurons and could indicate mitochondrial dysfunction (Betarbet et al., 2000). 
Together, these findings suggest that factors which modulate normal mitochondrial functioning 
may significantly compromise neuronal viability, suggesting a pivotal role for mitochondria in 
PD pathogenesis. 
Nigrostriatal dopaminergic neurons generate increased amounts of ROS, probably due to 
redox cycling of catechols. The presence of dopamine is considered one of the sources of 
oxidative stress that is unique and characteristic of dopaminergic neurons. Dopamine 
metabolism via monoamine oxidase (MAO) or amine autoxidation produces radical species: 
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H2O2, quinones and semiquinones (Graham, 1978), which promote the oxidation of lipids and 
other compounds, impairing mitochondrial function and increasing oxidative stress (Gluck et 
al., 2002; Sulzer et al., 2007; Naoi et al., 2009).  Furthermore, dopamine autoxidation occurs at 
neutral pH. Therefore, the uptake reduction of dopamine into synaptic vesicles, in which 
dopamine cannot autooxidize due to vesicle acid pH, may represent a vulnerability factor for 
these neurons. In agreement, neurons with reduced dopamine transporter activity in the cell 
membrane are less affected by oxidative stress caused by dopamine or neurotoxins (González-
Hernandez et al., 2004) and are also less affected in PD (Damier et al., 1999). 
Interconnection between oxidative stress and mitochondrial dysfunction is further 
suggested by an impairment of mitochondrial complex I due to chronic decrease of the 
antioxidant glutathione (Thiruchelvam et al., 2000). Furthermore, PPARgamma coactivator 1 
alpha (PGC-1α), which is involved in mitochondrial biogenesis and respiration, acts as a 
modulator of ROS production during oxidative stress (Lin and Beal, 2006). It was demonstrated 
that many ROS detoxifying enzymes like glutathione peroxidase-1, catalase and superoxide 
dismutase 2 (SOD2 or Mn-SOD) are regulated by PGC-1α upon oxidative stress. Concordantly, 
nigrostriatal dopaminergic neurons were more susceptible to parkinsonian neurotoxin MPTP in 
mice lacking PGC-1α. Moreover, neural cells were shown to be protected from oxidative stress-
induced cell death upon PGC-1α overexpression, evidencing its role as a potent regulator of 
ROS metabolism. The capacity of PGC-1α to increase the activity of mitochondrial electron 
transport chain and simultaneously stimulate a wide anti-ROS program, turns it an important 
target to restrict the damage that has been associated with defective mitochondrial function and 
oxidative impairment observed in PD and other neurodegenerative diseases (Bender et al., 
2006). 
Studies in postmortem brains suggest a prominent role for Nrf2/ARE (antioxidant response 
element) signaling in PD pathogenesis (Choi et al., 2006). The leucine-zipper transcription 
factor Nrf2 regulates the coordinated induction of the ARE activating the transcription of 
cytoprotective genes, including both antioxidant and anti-inflammatory proteins (Kraytsberg et 
al., 2006). Briefly, oxidation of a specific cysteine in Keap1 enables Nrf2 to migrate into the 
nucleus, where it activates the transcription of some genes that encode phase II detoxification 
enzymes, like NQO1, heme oxygenase 1 (HO-1), GCL, glutathione S-transferase (GST), and 
downregulates inflammatory enzymes such as inducible nitric oxide synthase (iNOS), 
cycloxygenase-2 (COX-2), among others (Chinta and Andersen, 2006; Ekstrand et al., 2007; 
Liang et al., 2007). In Nrf2 knockout mice, neurons were reported to be more susceptible to 
death due to mitochondrial dysfunction and oxidative stress (McGill and Beal, 2006; St-Pierre 
et al., 2006; Ramsey et al., 2007). Since both oxidative damage and inflammation have been 
implicated in PD pathogenesis, Nrf2/ARE pathway may constitute an important target for 
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therapeutic strategies (Lee and Johnson, 2004; Kobayashi et al., 2006). Phosphatidylinositol 3-
kinase (PI3K)/Akt (or protein kinase B) pathway is another promising pathway that has 
emerged in dopamine neuronal survival. Several findings reveal that overexpression of the 
oncoprotein Akt protected against 6-hydroxydopamine (6-OHDA)-induced dopaminergic 
toxicity. Akt seems to acts as a neurotrophic factor in dopaminergic neurons of adult and aged 
mice, leading to increased neuron size and sprouting (Itoh et al., 1999). In addition, familial PD-
linked proteins such as parkin (Feany and Pallanck, 2003), DJ-1 (Choi et al., 2006) and PINK1 
(Kim et al., 2005) are involved in mediating cell survival through the Akt pathway, sustaining 
an important role for Akt regulation in PD. Thus, it is becoming increasingly clear from 
multiple findings that both mitochondrial dysfunction and oxidative damage take a pivotal role 
in disease pathogenesis, contributing to sporadic and familial forms of PD. 
To sum up, the complexity of PD arises from a multitude of etiological factors involved in 
disease pathogenesis. Studies related with familial PD-linked genes tightly improved our 
knowledge of disease development beyond the more common sporadic form. At this point, there 
are several distinct pathways that are important in modulating pathogenic events causing the 
death of dopaminergic nerve cells in PD (Figure 1.5). 
 
 
Figure 1.5 - Schematic summary of the established intersecting pathways underlying PD pathogenesis in 
dopaminergic neurons. These pathways seem to converge on aspects that affect the function and survival 
of dopaminergic neurons due to oxidative damage, mitochondrial dysfunction and abnormal protein 
accumulation and phosphorylation. Promoting or activating effects are indicated by green arrows, while 
inhibitory effects are indicated by red lines with blunt ends. Based on Thomas and Beal, 2007 for review. 
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1.2.2.1. Iron homeostasis in neurodegeneration and relation with α-syn 
Many studies have confirmed an increase in iron (Fe) levels in the SN of most PD cases 
(Dexter et al., 1987; Riederer et al., 1989; Hirsch et al., 1991); however, the stage during 
disease progression at which nigral Fe alterations occurs is still debatable. It is known that total 
nigral Fe levels increase in PD, possibly contributing to nigrostriatal neurodegeneration as a 
result of its ability to generate ROS and cause lipid peroxidation (Youdim et al., 1991; Jomova 
et al., 2010). These raised Fe levels, besides contributing to the increase of oxidative stress, also 
enhance α-syn aggregation (Hashimoto et al., 1999). Fe is one of the most important elements 
for almost all types of cells, including neurons. It is an essential cofactor of various proteins 
related with normal function of neuronal tissues, such as the non-heme Fe enzyme and TH 
essential for the synthesis of the neurotransmitters dopamine, norepinephrine, and serotonin 
(Beard et al., 2003). In a healthy brain, Fe appears widely distributed by region and cell-type 
and its accumulation occurs progressively during aging and the neurodegenerative processes 
(Dexter et al., 1993). In mammals, Fe homeostasis (Figure 1.6) is mediated by the iron-
regulatory proteins (IRP1 and IRP2), which post-transcriptionally modulate the expression of 
specific mRNAs in response to intracellular Fe content (Hentze et al., 2004; Rouault, 2006). 
IRP1 and IRP2 proteins bind to structural elements called iron-responsive elements (IREs). 
IREs are found in the untranslated region (UTR) of the mRNAs of the transferrin receptor and 
ferritin, the major proteins that regulate cellular iron homeostasis, involving the plasma-to-cell 
iron transport, and the iron-storage, respectively (Aguirre et al., 2005). It has been demonstrated 
that α-syn harbors an IRE element in its 5’- UTR (Friedlich et al., 2007). Alternatively spliced 
α-syn mRNAs, which lack the IRE-like sequence encode 112 and 126 amino acid proteins that 
do not appear to nucleate and fibrillize with the full-length α-syn (Jellinger, 2003; Lee and 
Trojanowski, 2006). Thus, high intracellular Fe content may also regulate α-syn aggregation 
through the IRE/IRP system, leading to degeneration of dopaminergic neurons (Li et al., 2011). 
Other studies have revealed a potentially significant association between α-syn and iron (Binolfi 
et al., 2006; Bharathi, 2007). Indeed, α-syn can bind iron and this may be important for the 
normal activity of the protein, moreover α-syn overexpression significantly increased the 
percentage of Fe in cells (Davies et al., 2011). The same authors reported that α-syn is a cellular 
ferrireductase, responsible for reducing iron (III) to bio available iron (II) (Davies et al., 2011). 
As Fe deposits are commonly found in LBs (Castellani et al., 2000; Gaeta and Hider, 2005), Fe 
may play a pivotal role in α-syn pathogenicity in PD. 
As stated above, Fe can lead to the formation of ROS. Ferric iron (Fe
3+
) can be reduced to 
ferrous iron (Fe
2+
) by the superoxide radical (O2
•−
) (Fe
3+
 + O2
•−→ Fe2+ + O2). Fe
2+
 can also react 
with H2O2 generating the highly reactive hydroxyl free radical (
•
OH) (Fe
2+
 + H2O2 → Fe
3+
 +
 
•
OH + OH
−
), through the Fenton reaction (Jomova and Valko, 2011). Combining these reactions 
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will result in the Haber-Weiss reaction (O2
•−
+ H2O2 → O2 + 
•
OH + OH
−
), which along with 
dopamine oxidation can trigger neurotoxicity (Núñez et al., 2012). Therefore, the control of Fe 
homeostasis is a pivotal process to keep a healthy brain. 
 
 
 
Figure 1.6 - Homeostasis of Fe in the brain. Fe binds to transferrin (Tf), enters in the cell by endocytosis, 
through the transferrin receptors (TfR), and translocates across the endosomal membrane through the 
divalent metal transporter 1 (DMT1). Other pathway related to Lactoferrin receptors (LfR) that provides 
Fe transport from Fe containing lactoferrin across the cell membranes. Inside the cell Fe binds to H-
ferritin and accumulates around the neuromelanin. Ferroportin (Fpn) transports Fe
2+
 outside the neuron 
that is oxidized to Fe
3+
 by ceruloplasmin enabling its binding to Tf. Based on Batista-Nascimento et al., 
2012. 
1.2.3. Environmental factors 
Environmental factors were long thought to be the main cause that predispose to the 
development of PD. Rural environment appears to increase the risk of developing PD, and some 
epidemiological studies have demonstrated a correlation between exposure to pesticides and 
wood preservatives and a pre-disposition to develop the disease (Teismann et al., 2003). 
People intoxicated with MPTP developed a syndrome identical to PD (Langston et al., 
1983), this is an example of how an exogenous toxin can mimic the clinical and pathological 
features of PD. In humans and monkeys, MPTP exposure produced an irreversible and severe 
parkinsonian syndrome characterized by some features of PD, including slowness of movement, 
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postural instability, tremor, rigidity and freezing, accompanied by relatively selective 
dopaminergic neurodegeneration (Dauer and Przedborski, 2003 for review). In MPTP-treated 
non-human primates was observed the destruction of striatal terminals that preceded that of 
SNpc cell bodies (Herkenham et al., 1991). Moreover, and as in PD, monkeys treated with low-
doses of MPTP exhibited preferential degeneration of putamenal dopaminergic nerve terminals 
compared with those from caudate (Moratalla et al., 1992). This drug damaged the 
dopaminergic pathways in a pattern similar to that seen in PD, including greater cell loss in the 
SNpc and a preferential loss of neurons in the ventral and lateral parts of the SNpc 
(Sirinathsinghji et al., 1992; Varastet et al., 1994) this regional neurological loss pattern was 
also found in MPTP-treated mice (Seniuk et al., 1990; Muthane et al., 1994). After the 
discovery of MPTP-induced PD, subsequent research exploring the molecular basis of MPTP-
induced neurodegeneration established relationships between oxidative stress, mitochondrial 
function and neurodegeneration. MPTP blocks the mitochondrial electron transport chain by 
inhibiting complex I (Nicklas et al., 1987), and altered energy metabolism and generation of 
ROS were observed after toxin administration (Jackson-Lewis et al., 1995). Moreover, 
prolonged administration of low to moderate doses of MPTP to mice led to apoptosis of SNpc 
dopaminergic neurons (Tatton and Kish, 1997). MPTP and α-syn were also linked, indeed 
administration of this toxin led to the accumulation and nitration of α-syn in SNpc dopaminergic 
neurons (Vila et al., 2000; Przedborski et al., 2001), and ablation of α-syn in mutant mice  
prevents MPTP-induced dopaminergic neurodegeneration (Dauer et al., 2002). 
Rotenone, that inhibits mitochondrial complex I, is a mitochondrial poison present in the 
environment, and it is used as an insecticide (Sherer et al., 2003). Betarbet and colleagues 
(2000) showed that rotenone-treated rats developed slowness of movement and abnormal 
postures, and these symptoms were accompanied by selective degeneration of nigrostriatal 
dopaminergic neurons containing α-syn-positive LB-like inclusions. Nevertheless, this model 
was the first to link an environmental toxin to the PD pathological hallmark of α-syn 
aggregation, an association also observed in cell culture based experiments (Uversky et al., 
2001; Sherer et al., 2002; Lee et al., 2002). Paraquat is an herbicide present in the environment 
and shows structural similarity to MPP
+ 
(Dauer and Przedborski, 2003). Liou and coworkers 
(1997) reported that exposure to paraquat may confer an increased risk for PD. The toxicity of 
paraquat seems to be mediated by the formation of superoxide radicals (Day et al., 1999). Some 
reports indicated that administration of paraquat to mice led to SNpc dopaminergic neuron 
degeneration accompanied by α-syn containing inclusions, as well as α-syn immunostaining in 
frontal cortex (Manning-Bog et al., 2002; McCormack et al., 2002). 
Factors decreasing the risk of developing PD can also provide useful information to the 
understanding of the disease etiology. Many epidemiological studies have shown an inverse 
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association between cigarette smoking and PD (Grandinetti et al., 1994; Hernan et al., 2001; 
Paganini-Hill, 2001), reporting that patients who smoke are 50% less susceptible to develop PD 
when compared to non-smokers (Miller and Das, 2007). 
Some studies also found an association between coffee consumption and the risk for 
developing PD. It was reported in two cohort studies in men, a robust and significant inverse 
association between caffeine consumption and PD (Ross et al., 2000; Ascherio et al., 2001), 
while in a cohort of studies  in women, a poor association was found (Ascherio et al., 2001). 
1.3. SELECTIVE KINASES AND α-SYN PHOSPHORYLATION 
Increasing evidence suggest that phosphorylation may play a critical role in modulating α-
syn aggregation, LB formation, and toxicity (Fujiwara et al., 2002; Anderson et al., 2006). It 
has been demonstrated that α-syn deposited in LBs is highly phosphorylated at Serine (Ser)129 
(Kahle et al., 2000; Okochi et al., 2000; Fujiwara et al., 2002; Anderson et al., 2006) and Ser87 
(Paleologou et al., 2010). However, it is still not clear whether phosphorylation protects or 
enhances against α-syn toxicity in vivo. It was recently demonstrated that insufficiency of a pre-
synaptic scaffold protein Septin 4 (Sept4), involved in dopaminergic neurotransmission, can 
potentiate α-syn Ser129 phosphorylation, aggregation and toxicity in vivo, while a direct 
association of Sept4 with α-syn prevented Ser129 phosphorylation and α-syn aggregation in 
vitro (Ihara et al., 2007). However, it seems that the pathological modification of 
phosphorylated Ser129 of α-syn can be selective for neurons, and not for platelets from PD or 
multiple system atrophy patients (Shults et al., 2006). 
The role of phosphorylation in promoting or inhibiting fibril formation is still controversial. 
Phosphorylated α-syn at Ser129 has been reported to promote fibril formation more readily than 
unmodified protein, in vitro (Meulener et al., 2006), but inhibition of oligomerization and fibril 
formation has been also described for Ser87 or Ser129 phosphorylated forms of α-syn. An 
additional study using an in vivo model suggests a lack of correlation between the levels of α-
syn fibrillation and phosphorylation at Ser129 (Dick, 2006). More research is needed in order to 
obtain a coherent view of how phosphorylation alters the physiochemical properties of α-syn. 
Kinases and phosphatases responsible for regulating α-syn phosphorylation at Ser129 and Ser87 
in vivo are still not known; however, a series of in vitro and cell culture-based studies have 
identified several kinases, which phosphorylate α-syn at Ser129 and/or Ser87, including casein 
kinases (CK)-1(at Ser87 and Ser129) and CK-2 (at Ser129) (Okochi et al., 2000) and the GRKs 
(1, 2, 5, and 6, at Ser129) (Pronin et al., 2000), LRRK2 (at Ser129) (Qing et al., 2009a) and 
polo-like kinases (PLKs, at Ser129) (Inglis et al., 2009; Mbefo et al., 2010). 
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1.3.1. Casein kinases 
CK-1 and CK-2 have an ubiquitous expression; they are constitutively active kinases 
localized in the nucleus and the cytosol (Rinne et al., 1998; Gross and Lozano, 2000; Nyholm et 
al., 2005). Plasma membrane and cytoskeleton association of CK-1 and CK-2 has been also 
reported (Tuazon and Traugh, 1991; Ahmed, 1994; Limousin et al., 1998; Paleologou et al., 
2010). CKs are involved in diverse regulatory processes, suggesting a broad specificity and a 
variety of cellular protein substrates. Some findings indicate that CK-1, and specifically CK-2, 
are key players in the regulation of cell proliferation and transcriptional activity (Tawfic and 
Ahmed, 1994; Vancura et al., 1994; Walter et al., 1996). However, CK-1 and CK-2 have also 
been localized to synaptosomes (Issinger, 1993; Hollander et al., 1999) and shown to be capable 
to phosphorylate a number of synaptic vesicle proteins, like vesicle-associated membrane 
protein (VAMP), p65 and synaptic vesicle protein 2 (SV-2). Since α-syn was described to bind 
to brain vesicles (Guerra and Issinger, 1999) as well as small synthetic unilamellar liposomes 
(Bennett et al., 1993) and PD-associated mutations appear to affect α-syn membrane binding 
(Gross et al., 1995) these findings may be of particular interest. 
CK-2 is an ubiquitous and pleiotropic serine/threonine protein kinase, which was highly 
conserved during evolution, suggesting vital biological roles (Jensen et al., 1998). CK-2 activity 
and expression are significantly high in the brain (Davidson et al., 1998; Litchfield, 2003), 
where it is broadly distributed and primarily localized in neurons (Nakajo et al., 1987; Krebs et 
al., 1988). Furthermore, CK-2 has innumerous substrates and consequently controls many 
neuronal functions, including synaptic transmission, plasticity, development, neuritogenesis, 
information storage and survival (Girault et al., 1990). In addition, CK-2 phosphorylation has 
been related to the formation of neuronal cytoplasmic aggregates. For example, in AD studies, 
increased CK-2 immunolabeling has been demonstrated in neurofibrillary tangle-bearing 
neurons (Martin et al., 1990; Blanquet, 2000). In other neurodegenerative disorders, including 
the Guamanian Parkinson dementia complex, progressive supranuclear palsy and Pick disease, 
the association of CK-2 with tangles and other inclusions has also been reported (Iimoto et al., 
1990). Additionally, CK-2 is highly expressed in the hippocampus and rapidly activated during 
long-term potentiation (Masliah et al., 1992). Some neuronal proteins such as neuromodulin, 
dopamine- and cyclic AMP-regulated phosphoprotein of 32 kDa (DARPP-32) (Baum et al., 
1992) and microtubule-associated protein 1B (MAP-1B) (Charriaut-Marlangue et al., 1991) 
were shown to be phosphorylated by CK-2. Okochi and colleagues (2000) reported in an in 
vitro experiment that α-syn Ser129 phosphorylation was mediated by CK-1 and CK-2. 
Moreover, the same study revealed that phosphorylation of Ser129 was reduced in vivo upon 
inhibition of CK-1 or CK-2. Furthermore, CK-1 phosphorylation was reported to be activated in 
striatonigral neurons where dopaminergic neuron degeneration takes place specifically during 
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PD (Girault et al., 1989). Therefore, Ser129 phosphorylation may also be increased, particularly 
in these neurons, which may interfere in trafficking of dopamine-containing synaptic vesicles. 
Together, these findings suggest that CK-1 and CK-2 are involved in the regulation of neuronal 
function, and that phosphorylation of α-syn may affect its binding to membranes.  
α-Syn can be phosphorylated majorly at Ser129 and Ser87. Both Ser129 and the acidic 
sequence motif required for substrate recognition by CK-1 or CK-2 are also well conserved 
between several distinct mammalian species (Diaz-Nido et al., 1988). Indeed, a cognate 
recognition sequence for CK-1 encompasses Ser129 (Desdouits et al., 1995; Okochi et al., 
2000). Thus, Ser129 may be alternatively phosphorylated by CK-1 or CK-2. Interestingly, 
Ser87 phosphorylation seems to be specific for human α-syn and is the only one outside the C-
terminal region reported to undergo phosphorylation by CK-1 (Pearson and Kemp, 1991; 
Okochi et al., 2000). 
1.3.2. Polo-like kinases 
PLKs encompass a family of conserved serine/threonine protein kinases that play pivotal 
roles in cell cycle regulation, cellular response to stress and carcinogenesis. In mammalians, the 
PLK family consists of three closely related kinases PLK1, PLK2/Snk (serum-inducible kinase), 
PLK3/Fnk (fibroblast growth factor-inducible kinase) also designated Prk (proliferation-related 
kinase), and a distant member PLK4/Sak (Snk akin kinase) (Marshak and Carroll, 1991; Clay et 
al., 1993; Golsteyn et al., 1994; Hamanaka et al., 1994; Okochi et al., 2000). These PLKs share 
a conserved sequence motif characterized by two regions: a highly conserved N-terminal 
serine/threonine catalytic domain and a non-catalytic C-terminal domain designated Polo box 
domain (PBD) (Fode et al., 1994; Li et al., 1996). This PBD plays key roles in the regulation of 
substrate interactions, subcellular localization, targeting, and PLKs autoinhibition (Barr et al., 
2004). 
In addition to their key role in the regulation of cell cycle (Jackson et al., 2007 for review), 
PLKs are also expressed in different levels in post-mitotic cells, including neurons. PLK2 and 
PLK3 expression are induced by synaptic activation and appear to be involved in synaptic 
plasticity, remodeling, and homeostasis (Kauselmann et al., 1999; Cheng et al., 2003; Xie et al., 
2005) and have been also involved in the regulation of dendritic spine morphology. 
Furthermore, some findings using whole-genome microarray hybridization analysis revealed 
that PLK2 is indispensable for nerve growth factor-driven neuronal differentiation, since its 
silencing leads to neuronal differentiation inhibition (Seeburg et al., 2005). Previous studies 
showed that PLK2 has several properties that are particularly intriguing for an α-syn kinase as it 
was induced by excitotoxic glutamate agonists (Seeburg et al., 2008). In addition, some authors 
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have proposed that PLK2 has a pivotal role in maintaining dendritic spine stability (Draghetti et 
al., 2009) and modulating excitatory glutamatergic synaptic connections (Kauselmann et al., 
1999; Pak and Sheng, 2003). Thus, PLK2 involvement in phosphorylation of α-syn provides a 
potential link between excitotoxic responses and LB pathology. 
Some recent findings demonstrate that PLK2 can phosphorylate α-syn Ser129 (Inglis et al., 
2009; Mbefo et al., 2010). A study confirming these findings, demonstrated using in vitro 
kinase assays, co-transfection, and siRNA-mediated knockdown of PLKs, that α-syn is 
phosphorylated by specific members of the PLK family. PLK phosphorylates α-syn specifically 
at Ser129 and this mechanism seems to be mediated by specific interactions between the PLKs 
and the α-syn N-terminal region (residues 1–95) (Mbefo et al., 2010). These results were 
validated by co-localization assays, in which α-syn and PLKs co-localized in different 
subcellular compartments, as well as by co-transfection studies and siRNA-mediated 
knockdown of PLKs in primary neurons and other mammalian cells. PLK2 and PLK3 partially 
co-localized with α-syn phosphorylated at Ser129 in primary hippocampal neurons and also in 
cortical brain areas of α-syn transgenic mice. These results point out to PLK2 and PLK3 as the 
primary PLKs responsible for phosphorylation of α-syn at Ser129 (Inglis et al., 2009). 
Therefore, the physiological importance of α-syn phosphorylation by members of the PLK 
family can be supported by the following observations: i) PLK2 and PLK3 partially co-localized 
with α-syn phosphorylated at Ser129 in primary hippocampal neurons, mammalian cells and in 
cortical brain areas of mice overexpressing α-syn; ii) siRNA-mediated silencing of PLK2 or 
PLK3 resulted in marked reduction of nuclear and cytoplasmic Ser129 α-syn phosphorylation 
levels in mammalian cells and primary neurons; iii) PLK2 was expressed in normal brain and  
increased in AD and LBD brains, accordingly with previous reports demonstrating raised levels 
of PLK in the cytosol of vulnerable hippocampal and cortical neurons and homogenates of AD 
brains (Mbefo et al., 2008); iv) PLK2 was identified as a major contributor for α-syn 
phosphorylation in vivo and v) in PLK2 knock-out mice the levels of Ser129 α-syn 
phosphorylation were reduced by ~70% (Pak and Sheng, 2003). 
1.3.3. G protein-coupled receptor kinases  
G protein-coupled receptor (GPCR) signaling is regulated by GRKs. These kinases 
specifically recognize and phosphorylate agonist occupied GPCRs. Phosphorylation of the 
receptor and subsequent binding of another protein, arrestin, uncouples G protein from the 
activated receptor. These events can also promote receptor endocytosis. Internalized receptors 
are then dephosphorylated and recycled back to the cell membrane or targeted to lysosomes for 
degradation. Seven mammalian GRKs have been identified and can be divided into three 
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subfamilies based on their overall structural homology and organization: GRK1 (rhodopsin 
kinase) and GRK7; GRK2 (bARK1) and GRK3 (bARK2); GRK4, GRK5, and GRK6. GRKs 
share common features including a centrally localized catalytic domain of approximately 270 
amino acids, an N-terminal domain of around 190 amino acids that has been involved in 
receptor interaction and GRK regulation, and a C-terminal domain with a variable length of 
105–233 amino acids that is implicated in phospholipidic association (Pronin et al., 2000). 
Cytoskeleton plays a prominent role in assembly of signaling networks and is also involved 
in endocytosis and vesicular trafficking. Phosphorylation of tubulin mediated by GRK during a 
signaling event activates rearrangement of microtubules, thus contributing to receptor 
internalization, recycling or degradation (Carman et al., 1998; Haga et al., 1998; Pitcher et al., 
1998). It is also possible that GRKs may be involved in the regulation of signaling and 
cytoskeleton dynamics through phosphorylation of additional protein substrates. Thus, previous 
reports have demonstrated that co-expression of α-syn with GRK2 or GRK5 in COS-1 cells 
were able to phosphorylate α-syn at Ser129 (Pronin et al., 2000). 
Some findings have shown that GRK5 is accumulated in LBs in the brains of patients with 
non-familial forms of PD and can co-localize with α-syn in the pathological structures of the SN 
(Harris et al., 2000). In the same study, using a cell line stably expressing α-syn, the authors 
demonstrated that phosphorylation of α-syn at Ser129 depended on the expression levels of 
GRK5 and its kinase activity. Phosphorylated α-syn co-localized with GRK5 and α-syn, next to 
the plasma membrane. It was also concluded that GRK5 promoted the formation of α-syn 
soluble oligomers and aggregates through its phosphorylation. 
In a Drosophila model of PD, Ser129 phosphorylation of α-syn appeared to be critical for 
dopaminergic neurons toxicity. Furthermore, overexpression of Drosophila GRK2 increased α-
syn phosphorylation at Ser129, enhancing α-syn neurotoxicity (Pronin et al., 2000). Other 
results suggest no genetic association between GRK2 and sporadic PD, since no detection of 
GRK2 was observed in LBs from sporadic PD brains. Alternatively, it was found that GRK5 co-
localized with α-syn in double-transfected cells and in LBs of sporadic PD and that the 
susceptibility to sporadic PD was associated with haplotype of SNPs in the GRK5 gene. Some 
other findings pointed out that co-expression of human α-syn and WT GRK5 in dopaminergic 
neurons from C. elegans, resulted in phosphorylation of α-syn and produced a neurotoxic effect 
in these cells. These conclusions strongly support the hypothesis that phosphorylated α-syn by 
GRK5 may have a noxious effect on dopaminergic neurons (Harris et al., 2000). In contrast, 
other lines of evidence reported that endogenous GRK3 or GRK6 can phosphorylate α-syn at 
Ser129 in HEK293 cells, while endogenous GRK2 or GRK5 did not seem to have an essential 
role in the phosphorylation of α-syn in the same cell line (Sakamoto et al., 2009). 
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1.3.4. Leucine-rich repeat kinases 
While the pathogenesis of mutant α-syn is, at least in part, understood, the mechanism by 
which mutant LRRK2 can induce PD is not well clarified. LRRK2 is a large, multidomain 
GTPase/kinase protein that has the capacity to autophosphorylate in vitro (Chandra et al., 2004; 
West et al., 2005; Gillardon, 2009a; Gillardon, 2009b). The notion that altered signaling can be 
implicated in the disease came from the fact that the pathological mutations are within the two 
enzymatic domains of LRRK2 (Gloeckner et al., 2006). One of these mutations, G2019S, 
clearly increases kinase activity and is involved in PD pathology. At least, in neuronal cell 
models, kinase activity seems to be required for the toxicity of mutant proteins, (Greggio et al., 
2006; Greggio et al., 2008) further supporting the notion that alteration of LRRK2 signaling 
may have pathological implications. 
Several studies have focused on the functional link between α-syn and LRRK2. As 
described before in this section, α-syn present in LBs is highly phosphorylated at Ser129 and 
phosphorylated proteins appear to be more prone to aggregation in vitro (Fujiwara et al., 2002), 
suggesting a role in the neurodegenerative process. LRRK2 was hypothesized to be the kinase 
that mediates phosphorylation of α-syn. However, only one study indicated that recombinant α-
syn was directly phosphorylated by overexpressed LRRK2 in HEK293 cell lysates (Qing et al., 
2009a), while no other evidences exist for LRRK2-induced α-syn phosphorylation in cell or 
animal systems. It would be of interest to investigate whether pathological brain tissues from 
LRRK2 PD cases would lead to increased levels of phosphorylated α-syn. Some results reported 
that LRRK2 induced α-syn expression via the extracellular signal-regulated kinase pathway, 
although with a modest effect (Carballo-Carbajal et al., 2010). In one report, the authors (Qing 
et al., 2009b) successfully co-immunoprecipitated LRRK2 and α-syn from HEK293 cells 
exposed to oxidative stress and also from pathological tissue of diffuse LBs cases. These results 
are quite interesting since they leave the possibility that these two proteins can localize to the 
same cellular compartment upon stress, participating in a common biological process. 
Moreover, LRRK2 kinase activity may, directly or indirectly, influence α-syn phosphorylation 
state. Some other findings suggested that LRRK2 inclusions did not recruit α-syn when both 
proteins were co-overexpressed in cell systems (Waxman et al., 2009), leading to the idea that 
LRRK2 and α-syn deposition may constitute two independent processes. 
1.4. AVAILABLE THERAPIES FOR PD TREATMENT 
Several therapies have been proposed to treat or alleviate PD symptomatology.  There are 
several treatment strategies available for PD patients, including: oral medications (levodopa, 
MAOB inhibitors, dopamine agonists, anticholinergics, antiglutamatergics), surgical therapies 
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such as deep brain stimulation, continuous delivery therapies (transdermal patch, intraduodenal 
levodopa), among others (Obeso et al., 2010 for review). The use of carotid body tissue to treat 
PD has also been suggested because it is composed of glomus cells, which produce and secrete 
high levels of dopamine and, in addition, are resistant to hypoxia (Lopez-Barneo et al., 2001). 
Currently, clinical trials are being conducted with putative neuroprotective drugs, where glial 
cell line-derived neurotrophic factor (GDNF) can be included (Schapira et al., 2009), however 
none of these drugs has shown neuroprotective effects in these clinical trials (LeWitt and 
Taylor, 2008). 
1.4.1. GDNF 
GDNF and related molecules, such as Neurturin (NRTN), Artemin (ARTN) and Persephin 
(PSPN) belong to a structurally related family of neurotrophic factors (GDNF family ligands, 
GFLs) (Airaksinen and Saarma, 2002). GDNF is known to signal (Figure 1.7) through a multi-
component receptor system consisting of the glycosylphosphatidyl–inositol (GPI)-linked 
receptor GFRα1 (GDNF family receptor α1), and the co-receptor Ret (Takahashi, 2001; 
Paratcha et al., 2003; Sariola and Saarma, 2003). In embryonic and adult tissues from rodent 
origin, Ret is highly expressed in peripheral enteric, sympathetic and sensory neurons as well as 
central motor, dopamine and noradrenalin neurons, hence suggesting an important role of Ret in 
differentiation and survival of these cells (Takahashi, 2001).  
Since the discovery of GDNF by Lin and collaborators (1993) numerous cell culture 
experiments and rodent studies have demonstrated that this neurotrophic factor is active on 
different cell types in multiple tissues. GDNF is a neurotrophic factor for survival and axonal 
growth of mesencephalic dopaminergic neurons and has been shown to ameliorate motor 
symptoms and reduce brain damage in several animal models of PD (Gash et al., 1996; 
Björklund et al., 1997; Björklund et al., 2000; Kordower et al., 2000; Zurn et al., 2001). 
Grondin and co-workers (2002) presented evidence for structural and functional benefits of 
infusions of GDNF in MPTP-treated parkinsonian monkeys. This was the first demonstration 
that GDNF infused directly into the brain parenchyma of non-human primates is effective in 
restoring dopaminergic function. In the same study animal behavior recovery was accompanied 
by only a small increase in striatal dopamine levels, suggesting that GDNF may induce 
additional functional plasticity in the basal ganglia beyond mere increases in dopamine levels. 
Moreover, the authors suggested that GDNF may affect TH expression levels in neurons that 
were injured, by the MPTP treatment (Grondin et al., 2002). More recently, GDNF has 
demonstrated potent neuroprotective and restorative effects on dopaminergic nigral neurons, 
and thus may constitute a potential therapeutic strategy for PD (Deierborg et al., 2008; Lindvall 
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and Wahlberg, 2008; Marks et al., 2008). However, other reports have demonstrated the GDNF 
ineffectiveness on the amelioration of PD symptoms. Indeed, monthly injection of GDNF into 
the ventricles has been shown to be ineffective to ameliorate the symptoms of PD patients. 
Furthermore, several side effects were reported (Nutt et al., 2003), and there was no evidence of 
striatal dopaminergic reinnervation in a post-mortem studies (Kordower et al., 1999). Moreover, 
it has been demonstrated that excessive striatal GDNF expression resulted in downregulation of 
TH and abnormal axonal sprouting in downstream brain areas (Georgievska et al., 2002; 
Rosenblad et al., 2003). 
 
 
 
Figure 1.7 - Homodimeric GFLs activate Ret tyrosine kinase (TK) receptor by first binding their cognate 
GFRα receptors. Arrows indicate the preferred ligand–receptor interactions that are known to occur 
physiologically in vivo. Binding of Ca
2+
 ions to one of the four extracellular cadherin-like domains of Ret 
is required for its activation by GFLs. Four tyrosine residues in the Ret intracellular domain (Tyr905, 
Tyr1015, Tyr1062 and Tyr1096; red balls) serve as docking sites for different adaptors. One of them 
(Tyr1096) is in the carboxy-terminal end of the long isoform of Ret (grey). Membrane rafts are shown in 
yellow. ARTN, artemin; NRTN, neurturin; PSPN, persephin. Based on Airaksinen and Saarma, 2002. 
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1.5. OBJECTIVE 
As described throughout the literature review, α-syn aggregation and phosphorylation state 
play an important role in PD pathogenesis. Some reports demonstrated that α-syn deposited in 
LBs is highly phosphorylated at Ser129 residue, suggesting a role for phosphorylation in α-syn 
aggregation, LBs formation, and toxicity, although the later is still controversial (Fujiwara et al., 
2002; Anderson et al., 2006; Chen et al., 2009). A group of kinases have been suggested to be 
responsible for α-syn phosphorylation and subsequent aggregation, including PLKs (PLK1 and 
PLK2) (Inglis et al., 2009; Mbefo et al., 2010), CKs (CK-1 and CK-2) (Okochi et al., 2000) and 
LRRK2 (Qing et al., 2009a). On the other hand, several studies have confirmed an increase of 
Fe levels in the substantia nigra of PD patients, which may be involved in nigrostriatal 
neurodegeneration. Relatively recent investigations have found that FeCl2 exposure promoted 
the accumulation of Ser129 phosphorylated α-syn on 3D5 neuronal cell line overexpressing 
human WT α-syn (Takahashi et al., 2007). To reinforce this key aspect, our group has recently 
shown that α-syn phosphorylation at Ser129 is induced by FeSO4-induced oxidative stress in 
SH-SY5Y cells (Perfeito et al., 2010). Moreover, currently there is no effective treatment to PD. 
However, since the discovery of GDNF in 1993 (Lin et al., 1993), it has been proposed as a 
particularly potent neurotrophic factor for survival and axonal growth of midbrain dopaminergic 
neurons. Some evidences suggested that GDNF may offer potential protective strategies against 
the disease, although its efficacy was not always evident. According to these evidences, we 
hypothesized that in the presence of an oxidative stress agent (Fe
2+
) the phosphorylation state of 
α-syn could be affected, along with modified cell toxicity. On one hand, GDNF triggers a series 
of phosphorylation cascades and thus could promote α-syn phosphorylation, modifying its 
cytoprotective effect. On the other hand GDNF could prevent Fe
2+
-induced changes in α-syn 
phosphorylation. Another hypothetical assumption was that in the presence of α-syn 
phosphorylating kinase inhibitors, α-syn phosphorylation state as well as cell toxicity could be 
decreased. 
Based on these hypotheses, our main objective was to evaluate the role of selective kinases 
and GDNF in regulating the phosphorylation of α-syn in a specific serine residue (Ser129) in the 
absence and presence of Fe
2+
 using human neuroblastoma (SH-SY5Y) cells conditionally 
overexpressing wild-type α-syn (hereinafter referred to as α-syn), as a cell model of PD. 
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2.1. MATERIALS 
Optimem, Roswell Park Memorial Institute’s 1640 medium (RPMI 1640), fetal bovine 
serum (FBS) and Geneticin were purchased from GIBCO (Paisley, Scotland, UK). Protease 
inhibitor cocktail (chymostatin, pepstatin A, leupeptin and antipain), penicillin/streptomycin 
(P/S), albumin from bovine serum (BSA), nicotinamide adenine dinucleotide hydrate (NADH), 
pyruvate, Phenylmethanesulfonyl fluoride (PMSF), Bicine, 3-(Cyclohexylamino)-1-
propanesulfonic acid (CAPS), TWEEN, BIS-TRIS, Dithiothreitol (DTT), 
Tetramethylethylenediamine (TEMED), 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid 
(HEPES), doxycycline (Dox), hygromycin B, and alamar blue (resazurin) were from Sigma-
Aldrich (St. Louis, MO, USA). Fugene 6 was acquired from Roche Diagnostics GmbH 
(Mannheim, Germany). Secondary antibodies for western blotting anti-rabbit IgG, anti-mouse 
IgG+IgM  and Enhanced ChemiFluorescence reagent (ECF) were purchased from GE 
Healthcare (Little Chalfort, UK). Fluorogenic caspase-3 substrate VII Ac-Asp-Glu-Val-Asp-
AFC (Ac-DEVD-AFC), CK-1 inhibitor 4-(4-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)-5-pyridin-2-
yl-1H-imidazol-2-yl)benzamide (D4476) and LRRK2 inhibitor 2-((2-Methoxy-4-(4-(4-
methylpiperazin-1-yl)piperidine-1-carbonyl) phenyl) amino)-5,11-dimethyl-5H-benzo [e] 
pyrimido [5,4-b] [1,4] diazepin-6 (11H) - one      (LRRK2-IN-1) was from Calbiochem 
(Darmstadt, Germany). PLK1 inhibitor sodium (E)-2 - { 2-methoxy -5- [ (2',4',6'-
trimethoxystyrylsulfonyl) methyl ] phenylamino } acetate (ON-01910) and PLK2 inhibitor (R)-
4- (8-cyclopentyl- 7- ethyl- 5- methyl - 6 - oxo - 5, 6, 7, 8 - tetrahydropteridin – 2 – ylamino) -3-
methoxy-N-(1-methylpiperidin-4-yl)benzamide (BI2536) and CK-2 inhibitor 5-(3-
chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945) were purchased 
from Selleck Chemicals (Houston, Texas, USA). Glial cell-derived neurotrophic factor (GDNF) 
was from Peprotech (Hamburg, Germany). Polyvinylidene Difluoride (PVDF) membrane was 
acquired from Millipore (Billerica, MA, USA). Methanol was from Merck (Darmstadt, 
Germany). Bio-Rad Protein Assay was from Bio-Rad (Hemel Hempstead, UK). All other 
reagents were of analytical grade. 
2.2. METHODS 
2.2.1. Cell culture and maintenance of stable neuroblastoma SH-SY5Y cell 
line overexpressing WT alpha-syn 
Vekrellis and colleagues previously described (Vekrellis et al., 2009) the generation of a 
stable cell line conditionally overexpressing Wt α-syn. In resume, naïve SH-SY5Y cells were 
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transfected with the Tet-Off vector (Clontech, Mountain View, CA, USA) using the 
Lipofectamine 2000 reagent, and the selection process was carried out with 500 µg/ml geneticin 
(also known as G418). Inducibility of G418 resistant clones was determined by transient 
transfection of a pTRE-LUC vector, with or without the presence of Dox (2 µg/ml). One clone 
(2-22) was later used for generation of stable pTRE-α-syn expression. Wt α-syn was subcloned 
into the HindIII and XbaI sites of the pTRE-2 vector (Clontech) and co-transfected with the 
pTK-Hygromycin vector (Clontech). Selection was performed with 250 µg/ml G418 and 50 
µg/ml Hygromycin B. 
The instructions for maintenance and culture of stable SH-SY5Y cell line conditionally 
overexpressing Wt α-syn (SH-SY5Y Wt α-syn) were as follows: cells were cultured in RPMI 
1640 medium supplemented with 10% fetal bovine serum (FBS), 250 µg/ml G418 and 50 µg/ml 
hygromycin B and kept at 37ºC in an atmosphere of 95% air and 5% CO2. α-Syn overexpression 
was switched off with Dox (2 µg/ml). Stock cultures were always kept in the presence of Dox. 
For all the experiments cells were maintained for five to six days in the absence of Dox, a 
necessary condition for the maximal expression of WT α-syn in this particular cell line. The 
cells showed a highly tenuous basal expression in the presence of Dox and a strong expression 
of recombinant α-syn in its absence at day five/six. 
2.2.2. Incubation and stimulation of SH-SY5Y cell line 
In this section, incubation with compounds and stimulation procedures will be 
discriminated for all the subsequent assays. Kinase inhibitor solutions were prepared in 100% 
dimethyl sulfoxide (DMSO), and in all cases the % of DMSO in the culture medium was equal 
or inferior to 0.5%. CK-1 inhibitor was directly diluted into the aqueous cell culture medium, 
however, in order to promote its solubility and a better cell delivery, this compound was 
prepared accordingly to Rena and colleagues (2004). 
Cells were cultured as described above for all the experiments. As previously mentioned, 
the maximal expression of WT α-syn occurs at day five-six. As such, and for the cases with 24h 
of compound incubation, cells were plated at day four, incubated at day five and cell extracts 
were performed at day six. The respective assay was performed at day six or in the following 
days. For the cases with incubation for 2:30h or less, cells were plated at day four, the 
incubation and cell extracts were done at day five. The respective assay was performed at day 
five or in the following days. 
In Alamar Blue experience, 8.0x10
4 
cells/well were plated onto 48-multiwell plate. 
Incubations were done for 24h for all kinase inhibitors (ON-01910, BI 2536; D4476; CX-4945 
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and LRRK2-IN-1). A range of concentrations were tested (Table 2.1) for all inhibitors, in order 
to define which concentration could be used in all subsequent assays without cytotoxic effects. 
For the lactate dehydrogenase activity assay, 1.0x10
6 
cells/well were plated onto 6-
multiwell plate. Cell incubations were firstly done with FeSO4 (Iron (II) sulphate) 500µM 
(prepared in sterile water) for 24h and 2h in order to address its potential cytotoxic effect. In 
further experiences cells were incubated with selected inhibitors along with FeSO4. Inhibitors 
were incubated 30 min prior incubation with FeSO4 for 2h. Likewise, the procedure was 
repeated for the incubation with GDNF 20ng/ml (prepared in sterile water). 
In caspase-3 activity assay, 8.0x10
4 
cells/well were plated onto 48-multiwell plate. Cells 
were incubated for 24h with selected inhibitors or GDNF (20ng/ml), separately. 
For western blotting analysis, 5.0x10
6 
cells/well were plated onto 100 mm Petri dishes. For 
the time-course incubation with GDNF (20ng/ml), cells were incubated for different periods 
ranging from 5 min to 24h. In other immunoblotting experiences cells were incubated in 
different conditions, with selected inhibitors or GDNF 30 min prior incubation with FeSO4 for 
2h, and NaF 20mM (positive control for phosphorylation), 30 min before the end of incubation. 
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Table 2.1 - Range of kinase inhibitors concentrations tested on SH-SY5Y WT alpha-syn neuroblastoma 
cells. 
 
Kinase inhibitors 
 
Range of final concentrations in culture 
medium (µM) 
 
PLK1 
(ON-01910) 
 
0.05; 0.1; 0.5; 1; 2; 5 
 
PLK2 
(BI2536) 
 
0.01; 0.1; 0.5; 1; 2; 5 
 
CK-1 
(D4476) 
 
0.01; 1; 10; 100 
 
CK-2 
(CX-4945) 
 
0.01; 0.1; 1; 10; 100; 250 
 
LRRK2 
(LRRK2-IN-1) 
 
0.05; 0.1; 1; 2; 5; 10 
 
2.2.3. Subcellular fractionation - Total extracts 
Adherent cells were washed twice in ice-cold phosphate-buffered saline (PBS, in mM: 137 
NaCl, 2.7 KCl, 1.4 KH2PO4, 4.3 Na2HPO4.2H2O, pH 7.4) and then scraped in lysis buffer 
containing (in mM): 100 NaCl; 20 Tris (pH 7.0); 2 EDTA; 2 EGTA and supplemented with 1% 
Triton X-100, 0.1% SDS, 1 mM PMSF, 1 mM DTT, 50 mM NaF, 1.5 mM sodium 
orthovanadate, 0.1 μM okadaic acid and 1 μg/ml protease cocktail inhibitor (containing 
chymostatin, pepstatin A, leupeptin and antipain).  Cellular extracts were frozen/unfrozen 3 
times in liquid nitrogen, centrifuged at 14000 rpm, 10 min, 4ºC (Eppendorf Centrifuge 5417R) 
to remove cellular debris. The pellet was discarded, the supernatant (total extract) was collected 
and protein content quantified by the Bio-Rad method, according to the manufacturer’s 
instructions. Extracts were stored at -20ºC. 
2.2.4. Bio-Rad protein assay 
The Bio-Rad protein assay is a simple procedure with an appropriate degree of accuracy for 
determining the concentration of solubilized protein. This method is a dye-binding assay, in 
which a differential color change of a dye occurs in response to different concentrations of 
protein (Bradford, 1976).  
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A standard curve was prepared by adding 0, 1, 2, 3, 4, 5 μl of BSA 0.1% into each well 
(96-multiwell plate), 1 μl of lysis buffer and 120 μl of Bio-Rad reagent (diluted 3x). Final 
volume was adjusted to 200 μl/well with distilled water, to generate 0, 1, 2, 3, 4, 5 μg/μl of 
protein. Protein content was determined by adding 1 μl sample, 79 μl distilled water and 120 μl 
Bio-Rad reagent into each well. Subsequently, multiwell plate was incubated during 15 min at 
room temperature and protected from light.  Optical density was measured at 595 nm in a 
SpectraMax Plus 384 spectrophotometer. Protein concentrations (μg/μl) were calculated 
accordingly: x (y-b)/m, where y is the optical density, m is the slope of straight pattern and b is 
the intersection point with yy axis. 
2.2.5. Alamar Blue assay 
Alamar Blue is a cell viability indicator that uses the natural reducing power of living cells 
to convert resazurin to the fluorescent molecule, resorufin. The active component of Alamar 
Blue (resazurin) is a nontoxic, cell permeable compound that exhibits a dark blue color and has 
little intrinsic fluorescence. When taken into cells, resazurin is reduced to resorufin and turns 
red. Viable cells continuously convert resazurin to resorufin, thereby generating a quantitative 
measure of viability and cytotoxicity, based on its optical density or fluorescence (Fields and 
Lancaster, 1993; Al-Nasiry et al., 2007). 
Resazurin (1 mg/ml) was reconstituted in PBS and subsequently diluted (1:100) in RPMI 
1640 medium containing the selection antibiotics G418 (250 µg/ml) and Hygromycin B (50 
µg/ml), and finally added to SH-SY5Y WT α-syn cells in the presence or in the absence of Dox 
and incubated  for 2 h at 37ºC. Absorbance was detected at 570 nm and 600 nm in a SpectraMax 
Plus 384 microplate scanning spectrophotometer (Molecular Devices, USA). After the readings, 
cell protein content was determined by Bio-Rad method, as described above. Resazurin 
reduction was calculated upon subtraction of the absorbance at 570 nm by 600 nm. Results were 
expressed as O.D./mg protein or in % of control in accordance with the formula:  
 Abs570 – Abs600 treated cells
  Abs570 – Abs600 control cells
     
2.2.6. Lactate dehydrogenase (LDH) activity assay 
Membrane integrity was assessed by determining the release of the cytosolic enzyme LDH 
from the injured cells into the extracellular medium. This method represents a common assay to 
determine membrane leakage and cellular damage, typical of apoptotic or necrotic cell death. 
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After the incubation periods, the culture medium was collected for further assessment of 
extracellular LDH activity, whereas the adherent cells were scraped (with 100 μl of 10 mM 
HEPES, pH 7.4 with 0.5% of Triton X-100) in order to measure the intracellular LDH activity. 
All the samples were centrifuged at 14000 rpm, 10 min, 4ºC. The respective pellets were 
discarded and the supernatants were stored at -80ºC until used for the assessment of enzyme 
activity. For LDH intra and extracellular activity, and considering a final reaction volume of 200 
µl, 6.45 µl of each sample was mixed with 32.25 µl of pyruvate (9.76 mM). The reaction was 
started immediately after addition of 161.3 µl of NADH (0.24 mM). For the controls (blanks), 
NADH was replaced for Tris/NaCl pH 7.2 (81.3 mM of Tris and 203.3 mM of NaCl) which was 
also used to prepare pyruvate and NADH solutions.  
Enzyme activity was determined by following the rate of NADH consumption at 340 nm, 
performed at 30ºC, using a microplate reader SpectraMax Plus 384. The percentage of LDH 
released into the extracellular medium was calculated accordingly to the formula: 
% released LDH 
Extracellular LDH
(Extracellular LDH Intracellular LDH)
 100. 
2.2.7. Caspase-3 activity assay 
The assessment of caspase-3 activity was determined using a specific substrate, Ac (N-
acetyl)-Asp-Glu-Val-Asp-AFC (7-amino-4-trifluoromethylcoumarin) (Ac-DEVD-AFC). After 
washing two times with PBS, cells were lysed in a buffer containing (in mM): 25 HEPES, 2 
MgCl2, 1 EDTA and 1 EGTA and 0.04% Triton X-100, supplemented with 1 μg/ml protease 
cocktail inhibitor, 2 mM DTT and 0.1 mM PMSF. Then, a reaction buffer composed by 25 mM 
HEPES, 10% sucrose and 0.1% CHAPS, supplemented with 15 mM DTT and 15 µM Ac-
DEVD-AFC was added to cell samples. The fluorescence was taken during 1:30 h at 37ºC, with 
400 nm excitation and 505 nm emission, using a Microplate Spectrofluorometer Gemini EM 
(Molecular Devices, USA). After the readings, cell protein content was determined by Bio-Rad 
method, as previously described. The values were obtained as relative fluorescence units (RFU) 
per minute per mg protein for each condition, and subsequently expressed as % of control. 
2.2.8. Western blotting  
Total extracts, obtained as described above, were denatured with denaturing buffer (50 mM 
Tris-HCl pH 6.8, 2% SDS, 5% glycerol, 600 mM DTT, 0.01% bromophenol blue) at 95 ºC, for 
5 min. Equivalent amounts of protein were separated on a 12-15% SDS-PAGE gel 
electrophoresis and electroblotted onto polyvinylidene difluoride (PVDF) membranes. Prior to 
blocking step, membranes were incubated in a paraformaldehyde 0.4% (PFA) solution for 30 
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min, in order to enhance protein fixation. The membranes were then blocked during 1 h at room 
temperature in Tris-buffered saline (TBS) solution containing 0.1% Tween (TBS-Tween) and 
5% BSA, followed by an overnight incubation with primary antibodies (Table 3), at 4ºC, with 
gentle rotation. Membranes were further washed 3 times, for 15 min with TBS-Tween, and 
incubated with secondary antibodies (1:20000) for 1 h, at room temperature with gentle rotation. 
Proteins were visualized by using an enhanced chemifluorescent reagent (ECF) and the bands 
were detected by using a BioRad Versa Doc 3000 Imaging System. 
 
 
Table 2.2 - List of the primary and secondary antibodies used for western blotting analysis. 
 
Primary 
Antibody 
 
Molecular 
Weight 
 
Reference 
 
Dilution 
 
Secondary 
antibody 
 
Anti-Akt 
 
60 kDa 
 
#9272 (Cell 
Signaling) 
 
1:1000 
 
Rabbit 
 
Anti-P-Akt 
(Ser473) 
 
60 kDa 
 
#9271 (Cell 
Signaling) 
 
1:1000 
 
Mouse 
 
Anti-Ret 
 
170-175 kDa 
 
#3220 (Cell 
Signaling) 
 
1:1000 
 
Rabbit 
 
Anti-P-Ret 
(Tyr905) 
 
170-175 kDa 
 
#3221 (Cell 
Signaling) 
 
1:1000 
 
Rabbit 
 
Anti-α-syn 
 
18 kDa 
 
#2642 (Cell 
Signaling) 
 
1:1000 
 
Rabbit 
 
Anti-P-α-syn 
(Ser129) 
 
18 kDa 
 
#014 – 20281 
(Wako) 
 
1:500 
 
Mouse 
 
Anti-α-Tubulin 
 
50 kDa 
 
T6199 
(Sigma) 
 
1:1000 
 
Mouse 
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2.2.9. Statistical analysis  
Results were expressed as mean±SEM of the indicated number of independent 
experiments, run in duplicates or triplicates. Comparisons between multiple groups were 
performed using one-way or two-way analysis of variance (ANOVA), followed by Bonferroni 
post-hoc test, for comparison between experimental groups. Comparison between two groups 
was analysed using the Student´s t test or Bonferroni post-hoc test (GraphPad Prism Version 
5.0). P<0.05 was considered significant. 
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In this part of the thesis we first assessed the cytotoxic effect of PLK1, PLK2, CK-1, CK-2 
and LRRK2 kinase inhibitors and the oxidative stress agent (Fe
2+
, defined in this work as Fe) 
and GDNF. Furthermore, the selected kinase inhibitors as well as Fe and GDNF were evaluated 
in order to clarify its influence on α-syn Ser129 phosphorylation. 
3.1. EVALUATION OF CYTOTOXICITY OF KINASE INHIBITORS, Fe 
AND GDNF 
3.1.1. Effect of kinase inhibitors on cell viability assessed by the Alamar Blue 
assay 
The cytotoxic effects of the different kinase inhibitors used in this study were assessed 
using a cell viability assay, Alamar Blue. This assay uses the natural reducing power of living 
cells to convert resazurin (the active ingredient of Alamar Blue) to resorufin (Fields and 
Lancaster, 1993), giving a quantitative measure of cytoxicity. First of all, however, it was 
necessary to prove that the cell line was able to conditionally overexpress α-syn. Figure 3.1A 
shows clearly a highly tenuous basal expression in the presence of Dox and a strong expression 
of recombinant α-syn in its absence. In this way, it was proven the conditional overexpression of 
α-syn as well as the role of Dox as a switch for α-syn overexpression. Theoretically, –Dox 
condition (which leads to α-syn overexpression) mimics the duplication/triplication of α-syn 
gene (SNCA) observed in some familial cases of PD. In that sense, we examined if –Dox per se 
leads to an increase in cell toxicity. As depicted in Figure 3.1B, there is a significant decrease in 
cell viability, comparing –Dox with +Dox-treated cells. Interestingly, this observation is in 
accordance with the theory that postulates a toxic effect for α-syn overexpression in individuals 
with duplications/triplications of the locus containing SNCA (Lesage and Brice, 2009; Hatano 
et al., 2009). 
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In order to evaluate the potential cytotoxic effect of the different kinase inhibitors, a 
screening of concentrations for each inhibitor was performed, during 24 hours of incubation. 
Our defined range of concentrations included some concentrations indicated by other 
researchers and other concentrations that stand below and above these values. The inhibitors 
were dissolved in DMSO 100%, and for all the cases the percentage of DMSO present in the 
cell culture medium never exceeded 0.5%. The selected inhibitor concentration that will be 
applied in the subsequent experiments, should not give rise to a percentage of unviable cells 
superior to 20%. 
In the case of PLK1 inhibitor, ON-01910, we established a range of concentrations from 
0.05 to 5 µM (Gumireddy et al., 2005; Chapman et al., 2009; Oussenko et al., 2009; Tan et al., 
2009; Reddy et al., 2011; Chapman et al., 2012). By the analysis of the graph of PLK1 
inhibitor, the compound ON-01910 (Fig. 3.2A) revealed maintained cell viability in the 
presence of 0.167% DMSO used in cell culture medium. Each one of the concentrations tested 
of ON-01910 (0.05-5 µM) caused a decrease in cell viability higher than 20%; in the case of 
0.05 µM ON-01910 the percentage of cell viability was ~55% and ~66%, respectively, for 
Figure 3.1 - Assessment of SH-SY5Y neuroblastoma cell viability in a basal and pathological 
conditions, respectively, in the presence (+Dox) or absence (–Dox) of Dox. A) The expression levels 
of α-syn (18 kDa), in the presence or absence of Dox, were analyzed by Western Blotting in order to 
assess the conditionally WT α-syn expression system in SH-SY5Y human neuroblastoma cells. Total 
protein extracts were evaluated by Western Blotting using antibodies against α-syn and α-tubulin. B) 
Evaluation of cell reducing capacity through Alamar Blue reducing essay, in the presence or absence of 
Dox. Data, expressed in absolute values (33.944±1.268 O.D./mg protein for +Dox condition and 
28.568±1.173 O.D./mg protein for –Dox condition), are the mean±SEM of eighteen distinct 
experiments, run in triplicates. Statistical analysis was performed by Student’s t-test: **P < 0.01 when 
compared to +Dox-treated cells. 
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+Dox and –Dox. According to these results we decided to do not use this kinase inhibitor for the 
subsequent experiments. For PLK2 inhibitor, BI2536, a range of concentrations was defined 
(0.01-5 µM) in order to test its toxic effect on cells (Lénárt et al., 2007; Steegmaier et al., 2007; 
Nappi et al., 2009; Grinshtein et al., 2011; Watt et al., 2011; Waxman and Giasson , 2011). For 
BI2536 (Fig. 3.2B), the results were similar to those aforementioned for Fig. 3.2A, when testing 
the ranged concentrations. In the presence of 0.01 µM BI2536, we observed ~68% and ~80% 
cell viability, respectively, for +Dox and –Dox. For the remaining concentrations, the 
percentage values were below to those already referred, therefore this inhibitor was also 
discarded in subsequent experiments. 
For the specific case of CK-1 inhibitor, D4476, we defined a range of concentrations 
between 0.01 µM and 100 µM (Rena et al., 2004; Bain et al., 2007; Tillement et al., 2008; 
Huart et al., 2009; Waxman and Giasson, 2011). Regarding CK-1 inhibitor (Fig. 3.2 C), and the 
correspondent DMSO control, we observed slightly lower cell viability when compared to the 
two former inhibitors. DMSO (at 0.333%) slightly reduced cell viability, namely ~90% for 
+Dox and ~95% for –Dox, which were within the acceptable range of cell viability. The 
concentration of 10 μM led to a cell viability percentage very close to the threshold that defines 
a toxic concentration. CK-1 inhibitor with a concentration of 100 μM conduced to a situation of 
almost none viable cells. According to the data in the graph, one of the first three concentrations 
could have been selected for subsequent experiments, however, we chose the lower one, 
because it had the highest viability values, namely ~91% for +Dox and ~97% for –Dox. 
Relatively to CK-2 inhibitor, CX-4945, we have established a concentration range of 0.01 to 
250 µM (Drygin et al., 2009 ; Siddiqui-Jain et al., 2010; Pierre et al., 2011a; Pierre et al., 
2011b; Bliesath et al., 2012; Siddiqui-Jain et al., 2012). Regarding CK-2 inhibitor (Figure 
3.2D), DMSO (0.5%) in the cell culture medium induced ~90% of cell viability in both +Dox 
and –Dox condition. CX-4945 (at 0.01 µM or 0.1 µM) was within the concentrations for being 
chosen, and thus the lower concentration, exhibiting ~91% and ~89% cell viability for +Dox 
and –Dox, respectively, was selected. 
In the particular case of LRRK2 inhibitor, LRRK2-IN-1, we established a range of 
concentrations from 0.05 to 10 µM (Deng et al., 2011; Thévenet et al., 2011). Testing the dose-
response curve for the LRRK2 inhibitor (Fig.3.2E), DMSO (0.167%) induced ~99% cell 
viability in both +Dox and –Dox.  Analysis of cell viability in the presence of LRRK2-IN-1  
concentrations of 0.05-10 µM allowed the selection of 0.1 µM, since it showed ~94% and ~95% 
of cell viability, respectively, in +Dox and –Dox. 
From the graphs of the kinase inhibitors, representing cell viability according to different 
concentrations (Fig. 3.2 A-E), IC50 values (inhibitor concentration that causes a decline in cell 
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activity by 50%) can be calculated. These IC50 values (Table 3.1) were calculated for all the 
kinase inhibitors taking into consideration the presence or absence of Dox. All kinase inhibitors 
significantly inhibited cell viability at low micromolar concentrations in SH-SY5Y human 
neuroblastoma cells, with IC50 values ranging from 0.38±0.33 to 21.46±3.70 μM for +Dox and 
ranging from 0.64±0.49 to 24.36±2.70 μM for –Dox. 
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Figure 3.2 - Cell reducing capacity of SH-SY5Y neuroblastoma cells, in the presence of different 
kinase inhibitors, assessed by Alamar blue assay. Cells were incubated with or without Dox, and 
with a range of different inhibitor concentrations, for 24 h. Evaluation of cell reducing capacity 
through Alamar blue essay in the presence of: A) PLK1 inhibitor (ON-01910); B) PLK2 inhibitor 
(BI2536); C) CK-1 inhibitor (D4476); D) CK-2 inhibitor (CX-4945); E) LRRK2 inhibitor (LRRK2-
IN-1). For all the cases the %DMSO≤0.5%. Data, expressed as a percentage of control, are the 
mean±SEM of four distinct experiments, run in triplicates, for PLK1, PLK2 and CK-2 inhibitors and 
three distinct experiments, run in triplicates, for CK-1 and LRRK2 inhibitors. Statistical analysis was 
performed by two-way ANOVA, followed by Bonferroni post test: *P < 0.05, **P < 0.01,  ***P < 
0.001 when compared to respective control (untreated) cells. 
 
Kinase inhibitors IC50 values (µM) 
 
+Dox –Dox 
PLK1 
(ON-01910) 
0.38±0.33 0.64±0.49 
PLK2 
(BI2536) 
1.69±1.42 3.83±2.47 
CK-1 
(D4476) 
21.46±3.70 24.36±2.70 
CK-2 
(CX-4945) 
2.72±0.26 3.12±0.40 
LRRK2 
(LRRK2-IN-1) 
4.76±0.38 5.84±0.92 
 
Table 3.1 - IC50 values of selective kinase inhibitors in SH-SY5Y human neuroblastoma cell line. 
IC50 values were obtained by incubating SH-SY5Y cells with serial dilutions of the tested kinase 
inhibitors in the presence or absence of Dox, for 24 hours and assessing cell viability using the 
Alamar blue assay. Cells were treated with the kinase inhibitors in a range of concentrations of: 
ON-01910 (0.05-5 μM), BI2536 (0.01-5 μM), D4476 (0.01-100 μM), CX-4945 (0.01-250 μM) and 
LRRK2-IN-1 (0.05-10 μM). Values are shown as mean±SEM of four distinct experiments, run in 
triplicates, for PLK1, PLK2 and CK-2 inhibitors and three distinct experiments, run in triplicates, 
for CK-1 and LRRK2 inhibitors. 
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3.1.2. Effect of kinase inhibitors, Fe and GDNF on caspase-3 and LDH 
releaser 
Caspase-3 is a critical executioner of apoptosis; it is an effector caspase responsible for the 
proteolytic cleavage of many downstream key proteins (Fernandes-Alnemri et al., 1994). 
During apoptosis caspase-3 is activated by upstream caspases through proteolytic processing, 
giving rise to activated p17 and p12 fragments (Nicholson et al., 1995). Caspase-3 activity is 
only detected in lysates of apoptotic cells, which means that the apoptotic process is clearly 
installed. 
The previously selected inhibitors concentrations and GDNF (20 ng/ml) were thus 
subjected to analysis of caspase-3-like activity. According to data shown in Table 3.2, 
incubation for 24 hours with D4476 (0.01 µM), a CK-1 inhibitor, CX-4945 (0.01 µM), a CK-2 
inhibitor, or LRRK2-IN-1 (0.1 µM), a LRRK2 inhibitor, or GDNF (20 ng/ml) in SH-SY5Y cells 
treated in the absence of Dox caused non-significant changes on caspase-3-like activity, when 
compared to control conditions.  
Another way to quantify cell toxicity is through classical evaluation of plasma membrane 
integrity. Lactate dehydrogenase (LDH) is a stable cytosolic enzyme present in all cells and 
rapidly released into cell culture medium if any damage has occurred on plasma membrane. The 
amount of LDH released into the medium is proportional to the amount of unviable cells (e.g. 
Wolterbeek and van der Meer, 2005). 
Ostrerova-Golts and coworkers (2000) have confirmed that FeCl2 exposure led to iron-
induced toxicity in untransfected BE-M17 cells, as assessed by MTT and LDH assay. 
Moreover, they showed that, overexpression of α-syn (WT, A53T and A30P) enhances iron-
induced toxicity in BE-M17 transfected neuroblastoma cells. On the other hand, Takashi and 
colleagues (2007) found that FeCl2 treatment at 1 mM significantly increased ROS production 
in a time-dependent manner in 3D5 neuronal cell line overexpressing human WT α-syn. Our 
group has recently shown that exposure to FeSO4 (500 µM) for 2 hours evokes oxidative stress 
in SH-SY5Y neuroblastoma cell line (Perfeito et al., 2010). According to these findings, we 
decided to maintain the same concentration and incubation period for Fe, and incubate it with 
the selected kinase inhibitors or GDNF. Data in Table 3.3 show that incubation with Fe for 24 
hours decreased (rather than increased) LDH release in +Dox-treated cells (36.15±0.71%), 
although there was a trend for an increase in LDH release after incubation with Fe for 2 hours 
(42.05±0.58%), when compared to +Dox control cells (40.19±0.80%). Stimulation with Fe for 2 
hours showed a significant increase in LDH release when comparing with Fe exposure for 24 
hours. Regarding –Dox condition, we observed a trend of increased (although not significant) in 
LDH release after 24 hours (43.78±2.74%) and 2 hours (42.77±1.75%) of Fe exposure, as 
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compared to untreated –Dox control cells (41.28±1.28%). In relation to the effects of the kinase 
inhibitors, we observed that D4476 decreased (38.41±0.75%), whereas CX-4945 (46.52±1.48%) 
increases LDH release, when comparing with the other compounds. However, such tendency 
remains relatively unchanged when these two inhibitors are compared with Fe exposure for 2 
hours, in the absence of the inhibitors. Our results, although preliminary, indicate that there is 
no cell toxicity imposed by selected inhibitor concentrations, compared with the respective 
control cells, neither by LDH release nor by caspase-3-like activity assays. Notably, no 
significant changes in LDH release induced by GDNF in cells exposed for 2 hours with Fe have 
been found either (Table 3.3). 
 
 
 
 
 
 
 
 
 
 
 
  
Table 3.2 - Assessment of caspase-3 activity in cell lysates in the presence or absence of Dox.  
 
 Control D4476 CX-4945 LRRK2-IN-1 GDNF 
Caspase-3 
activity 
(% of control) 
(+Dox) 
100±2.51 --- --- --- --- 
Caspase-3 
activity 
(% of control) 
(-Dox) 
100±7.22 120.65±9.34 108.42±7.18 120.54±17.01 122.75±17.87 
Cells were incubated with D4476 (0.01 µM), CX-4945 (0.01 µM), LRRK2-IN-1 (0.1 µM) or GDNF 
(20 ng/ml), for 24 h. Data, expressed as a percentage of control (considering 204229.600±5146.776 
RFU/mg protein and 215894.000±37694.240 RFU/mg protein as 100%, respectively, for +Dox and –
Dox condition), are the mean±SEM of two distinct experiments, run in triplicates. 
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3.2. ASSESSMENT OF GDNF EFFECTS ON α-SYN PHOSPHORYLATION 
3.2.1. Time course of GDNF effects on Akt pathway activation 
GDNF activates the PI3K/Akt pathway through activation of Ret tyrosine kinase receptor 
in several contexts (Pong et al., 1998; Trupp et al., 1999; Focke et al., 2001; Jin et al., 2002). 
Ret cannot directly bind GDNF but requires the presence of GFRα1 (Treanor et al., 1996); it is 
through this multicomponent receptor complex that GDNF exerts its effects. SH-SY5Y cell line 
was previously reported to express Ret mRNA and Ret protein, as well as GFRα1 mRNA and 
protein (Hirata and Kiuchi, 2003). 
In an attempt to understand if our neuroblastoma cell line conditionally overexpressing α-
syn was expressing Ret receptor and if this receptor was activated, we performed a western 
blotting analysis (Fig. 3.3A). Two fragments migrate at 170 and 150 kDa corresponding to the 
mature high glycosylated and immature low glycosylated full-length Ret proteins, respectively. 
However, an extra fragment at 120 kDa was also detected, corresponding to the non-
glycosylated immature form of Ret protein, as described before (Takahashi et al., 1991; 
Takahashi et al., 1993). Either for the case of Ret or P-Ret the respective expression levels were 
Table 3.3 - Percentage of lactate dehydrogenase released into the cell culture medium in the presence 
or absence of Dox.  
 Control Fe (24h) Fe (2h) 
D4476 
+ 
Fe (2h) 
CX-4945 
+ 
Fe (2h) 
LRRK2-
IN-1 
+ 
Fe (2h) 
GDNF 
+ 
Fe (2h) 
% LDH 
released 
(+Dox) 
40.19±0.80 36.15±0.71 
t
* 
42.05±0.58 
t##
 
--- --- --- --- 
% LDH 
released 
(-Dox) 
41.28±1.28 43.78±2.74 42.77±1.75 38.41±0.75
 
t§§
 
46.52±1.48 41.62±0.76 
t§; t£
 
41.61±0.22
 
t§; t£
 
Cells were incubated with 500µM FeSO4 (Fe) for 24 h or 2 h. In the case of 2h of incubation with Fe, 
cells were incubated along with D4476 (0.01 µM), or CX-4945 (0.01 µM), or LRRK2-IN-1 (0.1 µM), 
or GDNF (20ng/ml), 30 min prior incubation with Fe. Data, expressed in percentage of lactate 
dehydrogenase released, are the mean±SEM of two distinct experiments, run in triplicates. Statistical 
analysis was performed by Student’s t-test:
  
t*
P < 0.05 when compared to respective control (untreated) cells. 
t##
P < 0.01 when compared to condition with Fe incubation during 24h. 
t§
 P < 0.05; 
t§§
 P < 0.01 when compared to condition with CX-4945 incubation along with Fe. 
t£
 P < 0.05 when compared to condition with D4476 incubation along with Fe. 
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low, however the expression levels of the former was more intense than the later for both +Dox 
and –Dox condition. To examine if GDNF was exerting any effect upon cells, we further 
investigated GDNF-induced signaling on Akt pathway activation. 
Due to small number of experiments there are significant deviations in the data, at some 
time points presented in the graph (Fig. 3.3C). Nevertheless, we observed a significant increase 
in Akt phosphorylation (on Ser473) in –Dox condition 10 minutes after stimulation with GDNF, 
when compared to +Dox GDNF-stimulated cells (1.42±0.27 and 0.84±0.04, respectively). This 
observation suggests the activation of Akt signaling pathway by GDNF, in a short period of 
time. 
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3.2.2. Time course of GDNF effects on α-syn phosphorylation  
GDNF has been linked for a whole series of phosphorylation cascades, which thus could 
also lead to α-syn phosphorylation. As can be seen in Figure 3.4B, there is a significant increase 
in α-syn phosphorylation at Ser129 in –Dox-treated cells after 2 hours of incubation with GDNF 
(20 ng/mL), as compared to +Dox-treated cells during the same stimulation period (1.47±0.37 
and 0.83±0.18, respectively). 
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Figure 3.3 - Effect of GDNF on activation of Akt pathway in human SH-SY5Y neuroblastoma 
cells conditionally overexpressing α-syn. Cells were incubated with or without Dox along with 
GDNF (20 ng/ml), for the length of time specified above the blots and displayed on the graph. A) 
Western blots demonstrating the presence of imature (120 kDa) and mature (170 kDa) GDNF 
receptor (Ret) and its active phosphorylated form (P-Ret) in total protein extracts from SH-SY5Y 
neuroblastoma cells. The extracts were evaluated by anti-Ret and anti-P-Ret (Tyr905) 
immunoblotting (labeled on the right). B) The expression levels of P-Akt (60 kDa) were analyzed 
by Western Blotting. α-Tubulin served as loading control. The blots illustrate two-three 
independent experiments represented in C). Data are the mean±SEM, normalized to Akt (60 kDa) 
and expressed as relative values of control. The average value obtained for control (untreated) cells 
was considered 1.0. Absolute values were 1.001±0.097 and 1.007±0.027, respectively, for +Dox 
and –Dox condition. Statistical analysis was performed by two-way ANOVA, followed by 
Bonferroni post test: **P <0.01 when compared to +Dox-treated cells. 
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Figure 3.4 - Effect of GDNF incubation time on phosphorylation levels of α-syn in SH-SY5Y 
cells. Cells were incubated in the presence or absence of Dox along with GDNF (20 ng/ml), for the 
length of time specified above the blots and as displayed on the graph. A) Western blots 
demonstrating the expression of α-syn and it phosphorylation level, at different GDNF stimulation 
time points, performed with total protein extracts from SH-SY5Y neuroblastoma cells. The extracts 
were evaluated by anti-P-α-syn (Ser129) and anti-α-syn immunoblotting (labeled on the right). α-
Tubulin served as loading control. The blots illustrate two to five independent experiments 
represented in the graph B), showing the data (mean±SEM) normalized to α-syn (18 kDa) and 
expressed as relative values of control. The average value obtained for control (untreated) cells was 
considered 1.0. Absolute values were 1.327±0.114 and 0.920±0.001, respectively, for +Dox and –
Dox condition. Statistical analysis was performed by two-way ANOVA, followed by Bonferroni 
post test: *P < 0.05 when compared to +Dox condition, during the same stimulation period (2h).  
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3.3. EVALUATION OF α-SYN PHOSPHORYLATION LEVELS 
3.3.1. Effect of kinase inhibitors, Fe and GDNF on α-syn phosphorylation  
Analysis of Figure 3.5B shows a significant increase (by about 50%) in α-syn (Ser129) 
phosphorylation levels following exposure to Fe (500 µM) for 2 hours, when comparing –Dox 
versus +Dox experimental conditions. Such findings seem to be in agreement with our initial 
hypothesis, according to which, in the presence of Fe the phosphorylation state of α-syn would 
be enhanced. Recently, our group has shown, in a similar approach, that a prolonged exposure 
(for 4 days) to Fe increased α-syn phosphorylation at Ser129 in a SH-SY5Y cell line transiently 
transfected with WT and mutant A53T α-syn (Perfeito et al., 2010). 
Relatively to incubation with GDNF (20 ng/ml) for 30 minutes plus 2 hours similar results 
were obtained when compared to data depicted in Fig. 3.4B. These observations seem to be in 
accordance with our initial suggestion, for GDNF as an inductor of α-syn phosphorylation. 
Considering that GDNF has been largely described to be a neurotrophic, pro-survival growth 
factor for dopaminergic neurons (Airaksinen and Saarma, 2002 for review), we verified if 
GDNF affected α-syn (Ser129) phosphorylation before a noxious stimulus such as Fe exposure, 
known to cause oxidative stress in SH-SY5Y cells (Perfeito et al., 2010). By analyzing the 
effect of a preincubation with GDNF for 30 minutes, followed by stimulation with Fe for 2 
hours, we found a trend for a decrease in both +Dox (0.45±0.14) and –Dox (0.87±0.13) 
condition, when compared, respectively, with Fe or GDNF incubations alone. These preliminary 
results suggest that although Fe and GDNF per se stimulate α-syn (Ser129) phosphorylation, the 
presence of the two stimuli inhibits α-syn phosphorylation, as neither of the stimuli exerted the 
previous observed effects. 
We next tested the effect of the selected kinase inhibitors upon α-syn (Ser129) 
phosphorylation increased levels evoked by Fe. All the inhibitors tested demonstrated a general 
decrease in α-syn phosphorylation when compared with respective –Dox cells stimulated with 
Fe. Nevertheless, the CK-2 inhibitor (CX-4945) caused a more pronounced decline (+Dox, 
0.44±0.10 and –Dox, 0.8±0.08) on α-syn phosphorylation, when compared to cells stimulated 
with Fe only (+Dox, 0.60±0.05 and –Dox, 1.19±0.20). For this reason, it seems to be the most 
promising inhibitor. These results, although preliminary and with no significant differences 
among groups, are in agreement with our first hypothesis for a potential protective role of 
selective kinase inhibitors under pathological conditions, herein modeled by the overexpression 
of α-syn. 
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Figure 3.5 - Effect of GDNF, Fe and selective kinase inhibitors on α-syn phosphorylation at 
Ser129. Cells were treated in the presence or absence of Dox, and depending on the conditions, 
exposed to Fe (500 µM), GDNF (20 ng/ml), D4476 (0.01 µM), CX-4945 (0.01 µM), or LRRK2-
IN-1 (0.1 µM). Considering the incubation periods, Fe was incubated for 2 h and GDNF for 2 h 
and 30 min. In the case of double incubation, GDNF or inhibitors were added in the medium 30 
min before incubation with Fe (2h). A) representative Western blots demonstrating the protein 
expression levels of α-syn and its phosphorylation at Ser129, performed with total protein extracts 
obtained from SH-SY5Y neuroblastoma cells. Membranes were probed with either specific 
antibodies to P-α-syn (Ser129) or α-syn. α-Tubulin was used as loading control. The blots illustrate 
five independent experiments represented in the graph B), showing the data (mean±SEM) of 
phosphorylated form of α-syn normalized to α-syn (18 kDa) and expressed as relative values of 
control. The average value obtained for control (untreated) cells was considered 1.0. Absolute 
values were 1.970±0.535 and 1.163±0.141, respectively, for +Dox and –Dox condition. Statistical 
significance: 
t*
P<0.05 comparing +Dox and – Dox condition with the same stimulus (by Student’s 
t-test). 
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Succinctly, our results demonstrated that α-syn overexpression triggered by the absence of 
Dox led to a decrease in cell viability when compared to cells incubated with Dox. We also 
showed that, with the exception of PLKs inhibitors, nanomolar concentrations of selected kinase 
inhibitors led to an acceptable percentage of viable cells. Moreover, assessment of plasma 
membrane integrity and caspase-3-like activity in cells exposed to the selected inhibitors, as 
well as FeSO4 (Fe, 500µM) and GDNF (20 ng/ml) did not reveal significant cytotoxic effects 
upon the cells. We also were able to demonstrate that GDNF induced the early activation of PI-
3K/Akt signaling pathway. Interestingly, Fe or GDNF exposure increased α-syn 
phosphorylation at Ser129. However, pre-incubation of GDNF prevented Fe-induced α-syn 
phosphorylation state. Finally, pre-incubation of cells with inhibitors of LRRK2 or CK-2 (in 
particular) followed by Fe exposure largely precluded Fe-induced stimulation of Ser129 α-syn 
phosphorylation. 
4.1. CYTOTOXICITY 
PD is characterized by the loss of mesencephalic dopaminergic neurons. Therefore, in this 
work we used a relatively homogeneous neuroblast-like cell line, known as SH-SY5Y, which 
provides an unrestrained supply of cells of human origin with comparable biochemical 
characteristics to human dopaminergic neurons. This cell line is useful as a model for 
dopaminergic neurons due to some particular characteristics: on one hand, SH-SY5Y cells 
possess the ability to synthesize dopamine and norepinephrine because the cells express key 
enzymes, like tyrosine and dopamine-β-hydroxylases (Oyarce and Fleming, 1991). On the other 
hand, these cells express dopamine receptors, as well as the dopamine transporter (DAT), a 
protein that is highly expressed in dopaminergic neurons only within the central nervous system 
(Takahashi et al., 1994); in addition, these cells have the capacity to express one or more 
neurofilament proteins (Ciccarone et al., 1989). Some compounds, like retinoic acid, are 
capable to induce differentiation, but confer tolerance to SH-SY5Y cells, and thus the role of 
toxicity or protection cannot be assessed in these differentiated cells (Cheung et al., 2009). This 
means that undifferentiated cells are an appropriate cell model for studying neurotoxicity or 
neuroprotection and hence become relevant in experimental PD research. 
To determine if the Tet-Off gene expression system, present in our SH-SY5Y cell line 
conditionally overexpressing α-syn, was correctly working, we analyzed the total protein 
extracts by western blotting in order to verify the expression levels of α-syn, in the presence or 
absence of Dox. The results showed a tenuous basal expression of α-syn in the presence of Dox 
and a robust expression in its absence. The functioning of the Tet-Off gene expression system 
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was proved and the results are in agreement with what was previous published (Vekrellis et al., 
2009). 
In several species, toxic events can be promoted by expression of α-syn. These include 
organisms such as yeast, flies and worms, where no α-syn homologue is present, indicating that 
irrespective of its normal function, this protein can be toxic. Induction of toxicity by α-syn 
expression was observed in vivo using vertebrate organisms. Indeed, delivery of either WT or 
mutant α-syn through viral vectors directly to substantia nigra in mice, rats and non-human 
primates showed significant dopaminergic cell loss accompanied by α-syn deposition (Cookson, 
2009, for review). Our cell line, besides being a good cell model of dopaminergic neurons it 
also conditionally overexpresses α-syn, mimicking the duplication/triplication of SNCA. It was 
documented that people with SNCA duplication have a brainstem-predominant PD phenotype 
(Chartier-Harlin et al., 2004), while triplication cases have a LB disease that involves several 
brain areas (Singleton et al., 2003; Fuchs et al., 2007). Measurements of α-syn levels in the 
blood of patients with SNCA triplication revealed a two-fold increase on α-syn protein levels, 
accompanied by increased levels and deposition of the protein in the brain cortex where LBs are 
found (Miller et al., 2004). Such genetic and biochemical evidences indicate that an increase in 
the levels of expression of WT α-syn is enough to cause neurodegeneration in PD. Furthermore, 
Iwata and coworkers (2001a) found that overexpression of WT or mutant forms of α-syn affects 
the cell viability of neuro2a cells, assessed in different perspectives. In the same study, the 
authors reported that WT, A30P and A53T α-syn inhibits MAPK (mitogen-activated protein 
kinase) signaling cascade and accelerates cell death, following serum reduction. Mutant and WT 
α-Syn overexpression attenuated not only the phosphorylation of classical MAPK ERK1-2 
(extracellular signal-regulated kinase 1-2), but also the phosphorylation of p38 MAPK and 
SAPK/JNK (stress-activated protein kinase/c-Jun N-terminal kinase). Moreover, suppression of 
MAPK phosphorylation occurred as the levels of WT or mutant α-syn expression increased, as 
assessed in inducible α-syn cell lines (Iwata et al., 2001a). Overexpression of α-syn decreased 
MAPK phosphorylation as well as c-fos gene expression (Blackshear et al., 1987; Hibi et al., 
1993; Derijard et al., 1994; Gould et al., 1995; Hodge et al., 1998). It was also reported that α-
syn directly binds ERK2, forming a complex with Elk-1 (ETS domain-containing protein Elk-1, 
an ERK2 substrate) (Iwata et al., 2001b). Furthermore, α-syn is known to block PLD 
(phospholipase D) activity in vitro (Jenco et al., 1998), which is greatly related to ERK1/2 
function (Wilkie et al., 1996; Ito et al., 1998). Thus, α-syn might regulate the MAPK pathway 
by decreasing the amount of available active MAPK. Considering this, α-syn may bind to a 
number of proteins in order to regulate signal transduction. Our results extend and reinforce the 
idea that α-syn overexpression per se may be toxic for the cells. Indeed, when we assessed the 
cell viability by the Alamar Blue assay in untreated cells, in the absence or presence of Dox, we 
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were able to observe a significant decrease in cell viability when Dox was absent, i.e. when α-
syn overexpression was induced.  
α-Syn may be modified post-translationally by truncation, nitration, ubiquitinylation and 
phosphorylation (Giasson et al., 2000; Fujiwara et al., 2002; Tofaris et al., 2003; Anderson et 
al., 2006). Such post-translational modifications have been explored as possible mediators of 
toxicity. In this work we focused on α-syn phosphorylation at Ser129. According to some 
authors phosphorylation at Ser129 is a α-syn modification that may play an important role in 
neurotoxicity and influence α-syn aggregation (Fujiwara et al., 2002; Anderson et al., 2006; 
Chen et al., 2009); however, this is still controversial as protein aggregates have been claimed 
to be less toxic than soluble oligomeric species (Wakamatsu et al., 2007; Gorbatyuk et al., 
2008). One possible approach to understand α-syn phosphorylation is to identify the key 
kinase(s) that mediates the transference of a phosphate group to Ser129. Several kinases have 
been proposed as candidates for α-syn phosphorylation at this residue. Such kinases were 
identified in in vitro and cell culture-based studies. These include CK-1 and CK-2 (Okochi et 
al., 2000), LRRK2 (Qing et al., 2009a), and PLKs (Inglis et al., 2009; Mbefo et al., 2010). 
Taking into consideration that post-translational modifications, such as phosphorylation may 
play a pivotal role in α-syn neurotoxicity, we can use selective inhibitors against these kinases 
and hence reduce the phosphorylation levels of α-syn. This strategy leads to the idea that α-syn 
toxicity could be diminished, and that is true only if one considers that phosphorylation may 
play an important role in α-syn neurotoxicity, which is not fully understood or proven.  
Based on these findings, we evaluated the role of five kinase inhibitors, namely ON-01910 
(PLK1 inhibitor), BI2536 (PLK2 inhibitor), D4476 (CK-1inhibitor), CX-4945 (CK-2 inhibitor) 
and LRRK2-IN-1 (LRRK2 inhibitor). Almost all of these inhibitors have been used in cancer 
research as cytostatic or cytotoxic agents. Thus, before starting the experiments with these 
inhibitors it was mandatory to perform an intense research, in order to ascertain the range of 
concentrations and incubation periods in our cell model.  
The PLK1 inhibitor used, ON-01910, is a cell-permeable non-ATP-competitive small 
molecule with a half-maximal inhibitory concentration (IC50) of 9-10 nM, and is entering phase 
III clinical trials for myelodysplastic syndrome (Gumireddy et al., 2005; Reagan-Shaw and 
Ahmad, 2005; Jackson et al., 2007; Chapman et al., 2012). During mitosis, PLK1 participates in 
centrosome maturation and assembly of the mitotic spindle. PLK1 is also involved in exit from 
mitosis and the segregation of sister chromatids during anaphase. Such kinase might also play a 
critical role in cytokinesis through the phosphorylation of the mitotic kinesin-like protein 1 
(MKLP1). For a normal regulation of cell-cycle processes the roles of PLK1 must be 
considered. It is involved in the entry to mitosis through the activation of cyclin-dependent 
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kinase 1 (CDK1) (Jackson et al., 2007 for review). PLK1 also participates on the regulation of 
tumour suppressors such as p53 and BRCA2 (Eckerdt et al., 2005). The inhibition of this kinase 
by small inhibitory molecules or siRNA has demonstrated to interfere with several steps of 
mitosis (Liu and Erikson, 2003; Sumara et al., 2004). Our data indicated that, ON-01910 
treatment using a concentration of 0.05 μM decreased cell viability, when compared with the 
respective DMSO-treated control cells. Such concentration was able to induce a cytotoxic effect 
beyond the stipulated non-toxic limit (of 80%). The same effect was observed for the remaining 
concentrations, in a dose-dependent manner. Several evidences are in agreement with our 
results. ON-01910 was previously tested against 94 different cancer cell lines, and in all of these 
cells this compound was found to induce apoptosis with a GI50 (the concentration required to 
achieve 50% growth inhibition) that ranged between 50–200 nM. In this group of human cancer 
cells, ON-01910 was found to result in the induction of mitotic arrest characterized by 
abnormalities in spindle formation, leading to the apoptotic death (Gumireddy et al., 2005). In 
another study, using ON-01910 in HeLa cells, PARP cleavage was reported in cells treated for 
24 hours, which became more pronounced after 48 hours of treatment, suggesting the 
progression of apoptosis in this cell line. In the same study, analysis of caspase-3 activity also 
demonstrated a huge upregulation of this activity in cells treated with 100 nM ON-01910 
(Gumireddy et al., 2005). Another study with leukemic cells shows that ON-01910 activated the 
mitochondrial apoptosis pathway by detection of activated Bax and Bak (pro-apoptotic proteins) 
and decreasing Mcl-1 (antiapoptotic protein) expression, leading to mitochondrial 
depolarization and caspase-3 activation (Chapman et al., 2009). More recently, the same authors 
working on the same type of cell line demonstrated that ON-01910 (2 µM) was capable to 
induce apoptosis through two main mechanisms of action: PI3K/Akt inhibition and induction of 
ROS (in a dose- and time-dependent manner), resulting in an oxidative stress response. It was 
revealed that ON-01910 treatment induced a classic ROS triggered response pathway that 
involved c-Jun N-terminal kinases (JNK) activation, accumulation of c-Jun in the nucleus, and 
induction of activating transcription factor 3 (ATF3) and NOXA in all leukemic cells tested 
(Chapman et al., 2012). Another possible mechanism for cell-cycle-arrest and apoptotic death 
triggered by ON-01910 is revealed in a work done with MCL (mantle cell lymphoma) cells. In 
this work, a decrease of cyclin D1 levels was observed by blocking cyclin D1 translation 
through inhibition of the PI3K/Akt/mTOR/eIF4E-BP signaling pathway; the authors also 
observed an altered expression of Bcl-2 family proteins, induction of mitochondrial cytochrome 
c release and activation of caspases (Prasad et al., 2009). To reinforce the cytostatic and 
cytotoxic effects of ON-01910, a recent study performed with DU 145 (prostate cancer) cells 
revealed a block of their cell-cycle progression and increase in cell death in a dose-dependent 
manner (0.1-1.0 µM) (Reddy et al., 2011). Such aforementioned aspects could explain the lower 
cell viability observed in our range of concentrations of ON-01910 (0.05-5µM).  
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PLK2 inhibitor, BI2536, is a cell-permeable ATP-competitive inhibitor selective for PLK1, 
with an IC50 value of 0.83 nM; nevertheless it can also affects the activity of PLK2, with an IC50 
value of 3.5 nM. The role of PLK2 on the cell cycle is still not well understood. During mitosis 
PLK2 is expressed and activated mainly during G1 and seems to interfere with G1 progression. 
PLK2 was shown to influence centriole duplication rather than centrosome segregation like 
PLK1. However, PLK2 activation is achieved through a mitotic checkpoint in a p53-dependent 
manner and thereby may prevent mitotic catastrophe after spindle damage (Reagan-Shaw and 
Ahmad, 2005 for review). Our results showed that a BI2536 concentration of 0.01 µM was 
sufficient to reach or to overcome the defined toxic threshold. Moreover, the remaining range of 
concentrations caused a more pronounced percentage of unviable cells, in a dose-dependent 
manner. It has been shown that BI2536 acts on cells through cell-cycle disruption and cell death 
via apoptosis. Indeed, BI2536 treatment (10, 30, and 100 nM) induces cell-cycle arrest and 10 
nM BI2536 induced a gradual accumulation of cleaved PARP fragments, suggesting apoptosis 
induction (Grinshtein et al., 2011). BI2536 (5-10 nM) caused cell-cycle arrest and detectable 
caspase-3 fragments (Nappi et al., 2009). Moreover incubation with BI2536 (60 nM) produced 
a strong signal for fragmented DNA and cleaved PARP (Steegmaier et al., 2007). Incubation 
with this PLK1/PLK2 inhibitor at concentrations of 5 and 10 µM also induced cell-cycle arrest 
and apoptosis (Watt et al., 2011). Taken together, these findings indicate that low nanomolar 
concentrations of BI2536 induce cell-cycle arrest and cell death by apoptosis. On the basis of 
the results of these researchers, it can be speculated that the cells in our Alamar Blue assay 
underwent cell-cycle arrest and/or apoptosis.  
D4476 was described as the more potent and selective cell-permeable CK-1 inhibitor; it 
acts as a potent, reversible and relatively specific ATP-competitive inhibitor of CK-1 with an 
IC50 value of 0.2 μM from Schizosaccharomyces pombe (Rena et al., 2004) and IC50 value of 
0.3 μM for CK-1δ isoform (Bain et al., 2003; Rena et al., 2004). More recently, other authors 
working on A375 cells demonstrated the possible inhibitor effect of D4476 upon CK-1α 
isoform (Huart et al., 2009). Among the CK-1 substrates there are enzymes, cytoskeleton 
proteins, membrane-associated proteins, transcription factors, splice factors, receptors and cell-
signaling proteins (Knippschild et al., 2005). It has been described that several CK-1 isoforms 
(α, δ and ε) phosphorylate p53 protein. This phosphorylation state is believed to attenuate the 
interaction between p53 and its inhibitory protein Murine double minute 2 (MDM2) and further 
stabilize the binding of the co-activator p300, resulting in p53 activation (Sakaguchi et al., 
2000; MacLaine et al., 2008). Moreover, the cross-talk between p53 and MDM2 on different 
levels relies on the phosphorylation state not only of p53, but also of MDM2. Interestingly, it 
has been also shown that several CK-1 isoforms (δ and ε) phosphorylate MDM2, which are 
involved in the degradation of p53 (Winter et al., 2004). These data suggest a pivotal role of 
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CK-1 in the modulation of p53 on cell growth and genomic integrity. This could be one of the 
reasons that lead the cells to undergo cell-cycle arrest or cell death, when CK-1 is inhibited. In 
our results, D4476 incubation caused a dose-dependent decrease in cell survival, when 
compared to respective DMSO-treated (control) cells. These findings are in accordance with 
those reported by Huart and colleagues (2009), in a study performed on A375 melanoma cells 
with increasing concentrations of D4476 (10-40 μM). The authors demonstrated a possible cell-
cycle arrest and apoptotic effect that increases with the concentration. Our results showed an 
increase in caspase-3-like activity (although not significant), with D4476 0.01 µM incubated for 
a period of 24 hours. It should be noted that the concentration we used for caspase-3 activity 
was 1000-fold lower than the minimal concentration used by the aforementioned authors. A 
possible explanation for the occurrence of the apoptotic event when cells are in the presence of 
D4476 may be due to the loss of E2F transcription factor 1 (E2F-1), which occurs in a dose-
dependent manner (Huart et al., 2009). E2F-1is a member of E2F family of transcription 
factors, which plays an important role in proliferation and differentiation controlling the 
transcriptional activity of genes required for controlling G1 to S phase transition in cells 
(Dyson, 1998 for review). Relatively to LDH assay, 0.01 µM D4476 incubated with Fe did not 
alter the toxicity pattern compared with cells treated with Fe alone for 2 h. However, this 
inhibitor induced a lower LDH release when compared to CX-4945 (0.01 µM) and LRRK2-IN-
1 (0.1 µM) in the same conditions.  
Several ATP-competitive inhibitors of CK-2 have already been indicated in the literature, 
among them the commercially available TBB and DMAT have been the most widely used in 
cell-based assays. However, a relatively recent evaluation of their inhibitory properties 
performed against a large panel of kinases indicated that their selectivity profile was not as great 
as originally believed (Pagano et al., 2008). None the described CK-2 inhibitors have reached 
human clinical trials. However, more recently the first orally available inhibitor of CK-2, CX-
4945, was discovered and is currently in clinical trials for the treatment of cancer. This small 
cell-permeable molecule is a potent, selective and ATP-competitive inhibitor of both isoforms 
of the CK-2 catalytic subunits, namely CK-2α and CK-2α´, with IC50 values of 1 nM (Siddiqui-
Jain et al., 2010; Ferguson et al., 2011; Pierre et al., 2011a). CK-2 is ubiquitously expressed, 
constitutively active, and has been demonstrated to play a crucial role in cell cycle control, 
cellular proliferation and differentiation. Indeed, CK-2 becomes an integral part of regulation of 
many anti-apoptotic and pro-proliferative signaling cascades, including PI3K/Akt and Wnt 
signaling cascades, NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) 
transcription, and DNA damage response (Duncan and Litchfield, 2008; Guerra and Issinger, 
2008 for review). Some findings suggest that CK-2 also phosphorylates pro-apoptotic proteins, 
protecting them from caspase-mediated cleavage, thereby acting as a suppressor of apoptosis 
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(Litchfield, 2003). A wide variety of cancer cells derived from tumors of different origin share 
abnormally high levels of CK-2 protein when compared with the respective normal cells 
(Tawfic et al., 2001). On the other hand, CK-2 has been associated to the regulation of EGFR 
activity as well as the downstream EGFR signaling pathways through multiple mechanisms 
(Pinna and Allende, 2009; Trembley et al., 2009). Another important role attributed to CK-2 is 
related with the phosphorylation and modulation of the activity of many members of the PI3K-
Akt-mTOR pathway including PTEN (phosphatase and tensin homolog), p70S6K (70 kDa 
ribosomal protein S6 kinase 1), and Akt (Torres and Pulido, 2001; Di Maira et al., 2005; 
Panasyuk et al., 2006). Hsp90 (heat shock protein 90) and the Hsp90 co-chaperone Cdc37, 
which could form a complex with many members of the EGFR signaling pathway, are both 
directly phosphorylated by CK-2 (Miyata, 2009; Porter et al., 2010). Furthermore, this kinase is 
responsible for phosphorylating and regulating the activity and stability of several tumor 
suppressor proteins, oncogenes and transcriptional activators (Seldin and Leder, 1995; 
Landesman-Bollag et al., 2001; Litchfield, 2003). Recently, it was reported that CK-2 plays an 
important role in DNA repair mechanisms, either in single or double DNA strand breaks (Koch 
et al., 2004; Loizou et al., 2004; Becherel et al., 2010). Two of the best characterized CK-2-
dependent DNA repair response substrates are XRCC1 (X-ray repair cross-complementing 
protein 1) and MDC1 (Mediator of DNA Damage Checkpoint protein1), which are 
indispensable elements, respectively, of the single strand break and double strand break repair 
machinery (Siddiqui-Jain et al., 2012). Our data regarding CX-4945 inhibitor showed a decrease 
in cell viability in a concentration-dependent manner. At 1 µM the inhibitor induced a cell 
survival profile inferior to the maximum acceptable percentage for cell viability (80%). The 
percentage of cell viability declined with increasing of inhibitor concentration, until a condition 
of none viable cells (CX-4945, 250 µM). The results provide some support to the cytostatic and 
cytotoxic effect of the inhibitor, already evidenced by many researchers. Indeed, CX-4945 (1 to 
10 µM) treatment for 24 hours induced cell-cycle arrest on cancer cell lines. In the same study, 
treatment with the same inhibitor (3-100 µM) during the same period of time showed caspase 
3/7 activation in a dose-dependent manner (Siddiqui-Jain et al., 2010). These findings were 
further supported by Pierre and colleagues (2011b). Very recently it was observed for the case 
of cancer cells stimulated with CX-4945 (10 µM), a percentage of viable cells similar to that 
found in our results using the same inhibitor concentration, although during a period of 
incubation of 96 hours. The same authors further observed a strong increase in caspase 3/7 
activity after CX-4945 (10 µM) exposure during 24 hours (Bliesath et al., 2012). Another recent 
study performed in ovarian cancer cells showed an anti-proliferative effect of cells treated with 
10 µM of CK-2 inhibitor during a period of incubation of 72 and 96 hours. Moreover, the same 
inhibitor concentration was able to induce cell-cycle arrest and increased caspase 3/7 activation, 
along with the appearance of cleaved PARP fragments, for 28 and 6 hours of stimulation, 
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respectively. Furthermore, CX-4945 incubation, again for the same concentration and for a 
period of 24 hours, prevented the activation of MDC1 and XRCC1 proteins and consequently 
suppressed the ability of cancer cells to repair DNA strand breaks (Siddiqui-Jain et al., 2012). 
We also performed an assay in order to evaluate caspase-3-like activity in SH-SY5Y cells, for a 
period of 24 hours and with a CX-4945 concentration of 0.01 µM. Our results showed a slight 
increase in caspase-3 activity; however, we must take into consideration the higher 
concentration used by the referred authors (1000-fold higher). Such difference in the results 
could also be explained, for example, by the fact that CX-4945 induced cell-cycle arrest in a 
different way on different cell lines, suggesting that cell-cycle regulation by CK-2 is cell-type 
dependent (Siddiqui-Jain et al., 2010). As already described in this thesis, CK-2 plays important 
roles in promoting pro-survival and anti-apoptotic pathways on cells and can interact with some 
key proteins in several signal cascades. Nevertheless, increasing attention has been paid to pro-
survival PI3K/Akt/mTOR pathway. It has been postulated that attenuation of the signalling of 
this pathway may enhance the induction of apoptosis, since CX-4945 inhibits CK-2 it can 
promote apoptosis via PI3K/Akt/mTOR pathway. This could be, among other reasons, a 
possible explanation for the occurrence of the apoptotic event when cells are in the presence of 
CX-4945. Indeed, Di Maira and colleagues (2005) showed that phosphorylation of Akt on the 
CK-2 specific site (Ser129) hyperactivates Akt. In a further study, these authors showed that 
phosphorylation at this residue facilitates the interaction of Akt with Hsp90, which in turn 
stabilizes the phosphate at Thr308 on Akt (Di Maira et al., 2009). It was demonstrated, in 
cancer cell lines, that CX-4945 induced a robust dephosphorylation of Akt (Ser129) as well as 
in canonical regulatory sites, Thr308 and Ser473 (Siddiqui-Jain et al., 2010). Notwithstanding 
the direct effects on the phosphorylation of Akt, it was also demonstrated that CX-4945 
treatment induced a decrease on phosphorylation of Cdc37 at the CK-2-specific site, Ser13 
(Bliesath et al., 2012). Cdc37 is an Hsp90 co-chaperone and CK-2-dependent phosphorylation 
of this co-chaperone is necessary for efficient binding of Cdc37 to the respective client kinases 
and it is also essential for the recruitment of Hsp90 to these Cdc37-client kinase complexes 
(Miyata, 2009). Moreover, Hsp90 itself is also a direct CK-2 substrate. Akt it is a Cdc37 client 
kinase and the disruption of such chaperone-kinase complexes by CX-4945 should contribute to 
decrease the activation of PI3K/Akt/mTOR pathway leading to the suppression of pro-survival 
signaling and a further apoptotic event. Regarding LDH assay, 0.01 µM CX-4945 incubated 
with Fe induce a slight increase in LDH release (although not significant). Indeed, this inhibitor 
at this concentration did not induce a toxic effect as assessed by Alamar blue assay.  
The LRRK2 inhibitor, LRRK2-IN-1, was described as the first selective and potent 
inhibitor of LRRK2. This is a cell-permeable compound that acts as a potent and selective ATP-
competitive inhibitor of LRRK2, with an IC50 values of 13 nM and 6 nM for WT and G2019S 
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mutant kinase, respectively (Deng et al., 2011). The same authors established that LRRK2-IN-1 
rapidly suppresses LRRK2 kinase activity leading to dephosphorylation of Ser910 and Ser935, 
loss of 14-3-3 binding and accumulation of LRRK2 within aggregate fibrillar structures. The 
normal physiological function of LRRK2 and its physiological substrates remains largely 
unknown (Li et al., 2010; Cookson, 2010). Nevertheless, some studies have been showing a few 
physiological substrates for LRRK2. It was reported that LRRK2 can efficiently phosphorylate 
ezrine, radixin, and moesin (ERM), proteins which anchor the actin cytoskeleton to the plasma 
membrane (Jaleel et al., 2007; Parisiadou et al., 2009). Moreover, it was revealed that LRRK2 
phosphorylates 4E-BP protein, which modulates stress sensitivity and dopaminergic neuron 
survival in Drosophila (Imai et al., 2008). More recently, it was reported that FoxO is also 
phosphorylated by LRRK2 (Kanao et al., 2010). Our results on cell viability using LRRK2-IN-1 
inhibitor show a decrease in cell viability in a dose-dependent manner. LRRK2-IN-1 at different 
concentrations caused a lower cell survival profile, when compared to respective DMSO-treated 
(control) cells. However, 1 µM induce a decrease in cell viability very close to the threshold that 
defines a toxic concentration, and cell viability subsequently declined with increasing inhibitor 
concentrations. This LRRK2 inhibitor was recently discovered and consequently only a few 
studies were performed so far. However, in a recent report, the authors did not observe any 
alteration on survival profile of the cells treated with LRRK2-IN-1 (10 µM), as assessed by 
Alamar Blue assay (Thévenet et al., 2011). These results do not support our observations; 
nevertheless it should be noted that the authors used a monocyte cell line, which suggests 
differential vulnerability of cell lines. Treatment of LRRK2-IN-1 (0.1 µM) for 24 hours showed 
a tendency for increased caspase-3-like activity. Several findings might explain this tendency 
for an increased activity of caspase-3. Kanao and colleagues (2010) have reported in human 
cells that FoxO is phosphorylared by LRRK2, which in turn upregulates the expression of Bim a 
pro-apoptotic protein. Several transcriptional targets of FoxO have been characterized, including 
molecules involved in cell cycle arrest, programmed cell death, oxidative stress and metabolism 
(van der Horst and Burgering, 2007). In an experiment carried out in LRRK2-deficient 
differentiated human mesencephalic neural progenitor cells, reduced number of dopaminergic 
neurons was observed due to apoptosis. Such cells also exhibited elevated cell cycle- and cell 
death-related markers. The same authors hypothesized that the absence of LRRK2 might impair 
the differentiation and/or survival of dopaminergic neurons and that this protein seems to be 
involved in cell-cycle regulation (Milosevic et al., 2009). Furthermore, gene array experiments 
in neuroblastoma cells also demonstrated that the absence of LRRK2 affects cell-cycle genes 
and p53 signaling cascades (Häbig et al., 2008). p53 activation can lead to either cell cycle 
arrest and DNA repair or apoptosis (Levine, 1997). In LRRK2-deficient dopaminergic cells, 
activation of p53 through phosphorylation was detected, which might influence cell death in 
these types of neurons (Nair et al., 2006). Impairment in autophagy-lysosomal pathway was 
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previously observed in LRRK2 knockout mice, which occurred concomitantly with the 
accumulation and aggregation of ubiquitinated proteins, which dramatically increases in 
apoptotic cell death, inflammatory responses and oxidative damage (Tong et al., 2010). 
Relatively to LDH assay, 0.1 µM LRRK2-IN-1 incubated with Fe induced no toxic effect 
compared with cells treated with Fe alone for 2 h. Further investigations will be required in 
order to clarify the cause of cell death in this particular SH-SY5Y cell line when treated with the 
selective kinase inhibitors used in this work. 
Iron is known to catalyze oxidative damage, through production of ROS. Since Fe
2+
 can 
react with H2O2 generating the highly reactive hydroxyl free radical (
•
OH) through Fenton 
reaction, an increase in the levels of this metal will favor the production of ROS and oxidative 
stress (Bossy-Wetzel et al., 2004; Jomova and Valko, 2011). Relatively to Fe cytoxicity in 
dopaminergic cells, it is generally accepted that total Fe levels increase in the substantia nigra 
in PD, possibly leading to nigrostriatal neurodegeneration, as a result of its ability to generate 
ROS and cause nucleic acids and protein damage, as well as lipid peroxidation (Youdim et al., 
1991; Jomova et al., 2010). Our results on cell toxicity, evaluated through the analysis of 
plasma membrane integrity, revealed a slight increase in the percentage of LDH released into 
the culture medium in –Dox cells (which model the duplication/triplication of SNCA gene) 
exposed to Fe for 2 h or 24 h, when compared with the respective control cells. Recently our 
group demonstrated that prolonged (for 4 days) and short (up to 2 h) incubations with iron led to 
an increase in the formation of endogenous peroxides in SH-SY5Y cells (Perfeito et al., 2010). 
A significant increase in the levels of ROS formation was demonstrated in SK-N-SH 
neuroblastoma cells when incubated with 1 mM ferrous iron (Li et al., 2011). In the same study, 
treatment with 100-300 µM ferrous iron for 24 h did not affect cell viability. However, using a 
concentration of 1 mM ferrous iron a significant decrease in cell viability was observed (Li et 
al., 2011). Nevertheless, the increase in LDH release was not as significant as expected. Some 
findings can contribute for a possible explanation. One of the critical roles of iron may be to 
participate in cellular defense response against the well-established capacity to induce oxidative 
damage. Indeed, when cells are iron-replete, but not in excess, aconitase enzyme is activated, 
resulting in elevated levels of intracellular L-glutamate. As a result, the production of GSH (L-
γ-glutamyl-L-cysteinyl glycine or reduced glutathione) may be stimulated, although the 
presence of L-cysteine is also mandatory (Lall et al., 2008). As a potent antioxidant, GSH 
maintains enzymes and protein thiols in their reduced state and scavenges ROS species (Reddy, 
1990; Gukasyan et al., 2003; Wu et al., 2004). Thereby the cellular oxidation state and potential 
to undergo oxidative damage can be reduced. Moreover, it was reported that SH-SY5Y 
neuroblastoma cells that survive an iron accumulation protocol evoke an adaptive response 
consisting of decreased synthesis of iron import transporter DMT1 (divalent metal transporter 1) 
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and increased synthesis of ferritin and ferroportin (Aguirre et al., 2005). Thus, cells can reduce 
the cytosolic content of Fe and avoid the well-known oxidative damage. Although speculative, 
these evidences could explain the small rather than large increase in LDH release. 
The different kinase inhibitors were incubated along with Fe (double incubation) in order 
to assess their potential synergistic toxic effect, evaluated by LDH release. From the data we 
concluded that no significant differences occur between control (untreated) cells, cells treated 
with Fe (for 2 hours) or Fe plus kinase inhibitors, indicating no synergistic toxic effects.  
In the case of GDNF stimulation our preliminary data showed no significant changes on 
caspase-3-like activity. Since the discovery of GDNF in 1993 (Lin et al., 1993) numerous cell 
culture experiments and rodent studies have demonstrated that it is active on different cell types 
in multiple tissues, acting as a particularly potent factor for survival and axonal growth of 
dopaminergic neurons. Moreover, several authors demonstrated that GDNF blocks the apoptotic 
event. The mechanisms by which GDNF exerts its effect are diverse, and some evidences 
highlighted that the rescue and repair of damaged neurons is a consequence of an anti-apoptotic 
action of GDNF. In fact, GDNF showed the ability to up-regulate Bcl-2 (B-cell lymphoma 2) 
and Bcl-XL (B-cell lymphoma-extra-large) levels in rat mesencephalic neurons subjected to 
apoptosis, resulting in the attenuation of apoptotic event and consequently of caspase activation 
(Kitagawa et al., 1998; Sawada et al., 2000). Later, Ghribi and collaborators (2001) confirmed 
these anti-apoptotic properties of GDNF by working with lysates of microdissected rabbit 
hippocampus. A more profound analysis of this scientific report revealed that after a direct 
(intracisternal) injection of aluminum complexes into rabbit brain this caused mitochondrial 
cytochrome c release, Bax translocation into mitochondria, a decrease in Bcl-2 in both 
mitochondria and ER, activation of caspase-3 and DNA fragmentation. Co-administration of 
GDNF inhibited these Bcl-2 and Bax changes, upregulated Bcl-XL, and strongly reduced 
caspase-3 activity, leading to a dramatic inhibition of apoptosis (Ghribi et al., 2001). A study 
performed in SK-N-SH neuroblastoma cells indicated that exogenous administration of GDNF 
inhibited both ethanol-induced apoptotic cell death associated with JNK cascade (McAlhany et 
al., 2000). Interestingly, expression of Ret was reported to induce apoptosis, which was blocked 
in presence of GDNF (Bordeaux et al., 2000). In a different approach, it was observed that 
addition of GDNF (100 ng/ml) had no effect on apoptosis in cultured glial cells, as assessed by 
caspase3/7 activity (Steinkamp et al., 2012). Our results indicated that GDNF did not induce the 
release of LDH. On the contrary, GDNF pre-incubation with Fe induced a slight reduction of 
LDH release into the culture medium, compared with incubation with Fe for 2 h. Although not 
significant these results are supported by the observation that GDNF exhibited a protective role 
against oxidative stress in cultured mesencephalic neurons and glial cells (Iwata-Ichikawa et al., 
1999). Moreover, Orth and colleagues (2000) reported no increase in trypan blue-positive cells 
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or LDH release into the supernatant in the presence of GDNF concentrations up to 500 ng/ml. 
Although performed on human adult mesangial cells (present in renal glomerulus) the authors 
used a concentration 25 times greater than the GDNF concentration (20 ng/ml) used in our 
study. 
4.2. α-SYN PHOSPHORYLATION LEVELS 
To evaluate if GDNF stimulates an intracellular signaling pathway in cells, we assessed the 
activation of Akt pathway through evaluation of Akt phosphorylation levels. GDNF activates 
the PI3K/Akt pathway through activation of Ret tyrosine kinase receptor in several contexts 
(Pong et al., 1998; Trupp et al., 1999; Focke et al., 2001; Jin et al., 2002). Ret cannot directly 
bind GDNF but requires the presence of GFRα1 (Treanor et al., 1996). Importantly, we were 
able to show that SH-SY5Y cells express Ret protein, in accordance with the prior detection of 
Ret mRNA and Ret protein as well as GFRα1 mRNA and protein (Hirata and Kiuchi, 2003). 
Our western blot results revealed the existence of three specific Ret fragments (120, 150 and 
170 kDa) in total cell lysates. Glycosylation of Ret occurs in the ER, and the molecular weight 
of this receptor increases from 120 kDa to 150 kDa (Takahashi et al., 1991; Takahashi et al., 
1993). Further glycosylation occurs in the Golgi apparatus and the molecular weight of mature 
Ret is approximately 170 kDa (Takahashi et al., 1991; Takahashi et al., 1993). In this context, 
we further evaluated the active form of Akt; we demonstrated an early increase of Akt 
phosphorylation at Ser473, which is indicative of the activation state of Akt (Kovacic et al., 
2003), 10 minutes after stimulation with GDNF in –Dox cells. Other authors showed that 
GDNF stimulates Akt phosphorylation at different time points in different cell types and with 
different GDNF concentrations (Mograbi et al., 2001; Paratcha et al., 2001; Hauck et al., 2006). 
GDNF concentrations used by these authors was significantly higher (100 ng/ml and 50ng/ml) 
than the concentration of GDNF used in the present study (20 ng/ml). These findings seem to 
indicate that the time point for GDNF-induced phosphorylation of downstream substrates is 
cell- and dose-dependent. Lack of sustained increase in Akt phosphorylation observed in our 
cells might be explained by the expression of high levels of immature Ret; indeed, we observed 
a relatively strong expression of non-glycosylated immature Ret form (120 kDa), when 
compared with 150 and 170 kDa. Therefore, we may hypothesize that the absence of a 
functional mature Ret abrogates the ability of GDNF to trigger sustained intracellular signaling 
in our cells.  
Taking into account that GDNF activates intracellular phosphorylation cascades, we further 
analyzed the role of GDNF on α-syn phosphorylation state at Ser129. Interestingly, we showed 
an increase on phosphorylation rate after 2 hours of GDNF incubation in the absence of the 
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stress stimuli (Fe) in cells overexpressing α-syn (-Dox), which is seen in independent 
experiments which data is depicted in Figs. 3.4B and 3.5B (a trend is shown in this last data). 
Although so far, and according to the scientific literature, no one has reported the influence of 
GDNF on α-syn phosphorylation levels, these data are worthwhile to be explored taking into 
account that GDNF protective effects are not always clear-cut (Kordower et al., 1999; Nutt et 
al., 2003). 
Considering that GDNF has been largely described to be a neurotrophic, pro-survival 
growth factor for dopaminergic neurons (Airaksinen and Saarma, 2002 for review), we verified 
if GDNF affected α-syn (Ser129) phosphorylation before a noxious stimulus such as Fe 
exposure, known to cause oxidative stress in SH-SY5Y cells (Perfeito et al., 2010). As 
described previously, some authors have previously demonstrated that the levels of Ser129 
phosphorylated α-syn are increased after treatment with ferrous iron, which causes cellular 
oxidative stress (Takahashi et al., 2007; Perfeito et al., 2010). Interestingly, we observed a 
significant increase in α-syn (Ser129) phosphorylation levels following Fe exposure comparing 
–Dox vs +Dox cells. We have also demonstrated a slight increase in Ser129 phosphorylated α-
syn, by comparing control (untreated) cells with Fe-treated cells in –Dox condition. There are 
several evidences that may contribute to understand such finding. As described before in this 
thesis, elevated iron levels were observed in individual dopaminergic neurons of PD patients’ 
brains as well as in the SN of PD models (Dexter et al., 1989; Good et al., 1992; Martin et al., 
2008; Oakley et al., 2007; Riederer et al., 1989; Zecca et al., 2005). Elevated levels of iron were 
also found in the LBs of the parkinsonian SN (Hirsch et al., 1991). Neuropathological studies 
revealed that synucleinopathies are in general associated with increased levels of iron, which is 
in accordance with a pathological link between iron and α-syn (Duda et al., 2000). It is 
considered that oxidative stress contributes to the cascade of the neurodegeneration, resulting 
from enhanced levels of redox-active iron within the SN (Berg and Hochstrasser, 2006; Bush, 
2000). An in vitro study showed that Fe could accelerate purified α-syn to aggregate rapidly 
(Golts et al., 2002). Exposure of cells to iron together with dopamine or hydrogen peroxide 
(other free radical generators), was able to induce α-syn aggregation (Ostrerova-Golts et al., 
2000). Concordantly, Li and coworkers (2011) suggested that intracellular α-syn aggregation 
induced by Fe is partially dependent on oxidative stress. Increasing evidence suggest that 
phosphorylation may play a critical role in modulating α-syn aggregation, LBs formation and 
toxicity (Fujiwara et al., 2002 ;Anderson et al., 2006). Phosphorylated proteins, namely 
phosphorylated (Ser129) α-syn appear to be more prone to aggregation in vitro and in vivo 
(Fujiwara et al., 2002; Gorbatyuk, et al., 2008). As described before, it has been demonstrated 
that α-syn deposited in LBs is highly phosphorylated at Ser129 (Kahle et al., 2000; Okochi et 
al., 2000; Fujiwara et al., 2002; Anderson et al., 2006). Our group has recently shown that α-
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syn phosphorylation at Ser129 is induced in a SH-SY5Y cell line by oxidative stress exerted by 
prolonged exposure (for 4 days) to Fe (Perfeito et al., 2010). Similar results were obtained by 
Takahashi and colleagues (2007).  
Following pre-incubation of GDNF and exposure to Fe, we observed a reduction of α-syn 
(Ser129) phosphorylation, compared with Fe alone. These data suggest that GDNF is important 
to reduce α-syn phosphorylation induced by oxidative stress. As described before in this work, 
GDNF was shown to exhibit a protective role against oxidative stress in cultured neurons and 
glial cells (Iwata-Ichikawa et al., 1999). Such findings seem to indicate that GDNF could reduce 
the potential oxidative stress induced by Fe and consequently reduce α-syn phosphorylation rate 
and potentially its aggregation. Thus, GDNF could protect cells from the potential toxic effect 
of Ser129 phosphorylated α-syn, although this was not proven in the present study. Unpublished 
data from our group (Perfeito et al.) showed that Fe
2+
-induced α-syn (Ser129)phosphorylation 
occurred concomitantly with a slight but significant increase in propidium iodide labeling in 
SH-SY5Y cells, suggesting that some cells have undergone loss of plasma membrane integrity 
and thus necrotic cell death. These data suggest a correlation between Fe
2+
-induced α-syn 
(Ser129) phosphorylation and cell death. Moreover, it was previously reported that SH-SY5Y 
neuroblastoma cells survived to an accumulation of iron, such survival response are related with 
decreased synthesis of DMT1 and increased synthesis of ferritin and ferroportin (Aguirre et al., 
2005). Thus, cells can reduce the cytosolic content of Fe and avoid oxidative damage. Such 
finding along with the idea that GDNF exhibit a protective role on neurons against oxidative 
stress, suggests a possible preventive effect of GDNF against the noxious effects induced by Fe, 
i.e., herein defined by a rise in α-syn phosphorylation. 
Phosphorylation of α-syn at Ser129 is characteristic of PD and related α-synucleinopathies. 
Unraveling the role of phosphorylation in modulating the physiological and pathogenic 
activities of α-syn requires identification of the kinases and phosphatases that may regulate its 
phosphorylation. Kinase inhibitors have been used for understanding the physiological roles of 
their targets. Thus, by using selective kinase inhibitors, we evaluated the role of some kinases in 
regulating α-syn phosphorylation. 
In this study we used conditionally WT α-syn overexpressing cells under Fe exposure as an 
experimental model to study α-syn phosphorylation. A similar strategy was previously used by 
Takahashi and collaborators (2007). We focused on WT α-syn, because genomic 
duplication/triplication of WT α-syn was previously linked to familial forms of PD (Singleton et 
al., 2003). Moreover, environmental factors, including oxidative stress, are considered to play a 
critical role on PD pathogenesis (Sherer et al., 2002). α-Syn can undergo several post-
translational modifications (Dev et al., 2003). Ser129 phosphorylation is thought to be one of 
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the most important events among such modifications (Fujiwara et al., 2002; Kahle et al., 2002; 
Takahashi et al., 2003; Anderson et al., 2006), because immunohistochemical and biochemical 
studies have revealed that almost 90% of α-syn in LB is phosphorylated at Ser129 (Fujiwara et 
al., 2002; Anderson et al., 2006) and that the Ser129 phosphorylation is closely associated with 
aggregate assembly in cellular models (Smith et al., 2005b). It was also suggested that α-syn 
phosphorylation at Ser129 plays a key role in α-syn-related cell death; one of the cell culture-
based study was performed on α-syn-overexpressing SH-SY5Y cells (Sugeno et al., 2008). 
However other reports have suggested no link between α-syn phosphorylation at Ser129 and cell 
toxicity; instead the authors suggested that α-syn phosphorylation at Ser129 may protect nigral 
dopaminergic neurons from neurodegeneration. Studies performed in a rat model of PD, 
revealed that overexpression of α-syn mutant S129A (which cannot be phosphorylated) was 
toxic for dopaminergic neurons, overexpression of α-syn mutant S129D (which mimics 
constitutive phosphorylation) produced no obvious toxicity and overexpression of WT α-syn 
revealed an intermediate toxic effect (Gorbatyuk et al., 2008). Moreover, accumulation of A53T 
mutant α-syn phosphorylated on Ser129 was not associated with toxicity (Wakamatsu et al., 
2007). These findings led us to speculate that if Fe-induced increased levels of Ser129 α-syn 
phosphorylation can be reduced by pre-incubation with inhibitors molecules, therefore the 
respective kinase might be involved in α-syn phosphorylation. Moreover, such kinase inhibition 
can even be protective for dopaminergic neurons, if we consider that Ser129 α-syn 
phosphorylation plays an important role in the fibrillogenesis, LB formation, and neurotoxicity, 
as already mentioned in this study. Thus, we evaluated the potential role of three different 
kinases (CK-1, CK-2 and LRRK2) on α-syn phosphorylation, by using selective inhibitor 
compounds, under non-toxic concentrations. In vitro and in vivo studies have shown that both 
soluble and fibrillized α-syn can be a substrate for CK-1, at Ser129 (Okochi et al., 2000; 
Waxman and Giasson, 2008). Inhibition of CK-1 with D4476 demonstrated no major reduction 
on α-syn phosphorylation. Indeed, a previous study indicated that inhibition of CK-1 (using 
D4476) had no effect on α-syn phosphorylation at Ser129 (Waxman and Giasson, 2011). 
Nevertheless, Okochi and colleagues (2000) reported that α-syn phosphorylation at Ser129 was 
reduced in vivo upon inhibition of CK-1; however such kinase was inhibited with a different 
molecule. Despite the fact that some authors recommend the use of D4476 to inhibit CK-1 
isoforms in cell-based experiments (Bain et al., 2007), these findings seems to indicate that 
D4476 does not significantly inhibit CK-1 in our PD cell model.  
So far, there is only one published in vitro study demonstrating that both WT and G2019S 
mutant LRRK2 and its kinase domain-containing fragments have a significant capacity to 
phosphorylate α-syn at Ser129 (Qing et al., 2009a). However, other studies in cell cultures and 
animal models, in which WT or PD related G2019S LRRK2 was overexpressed, failed to 
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identify any increase on Ser129 phosphorylated α-syn (Liu et al., 2012). Our results show a 
tendency for a slight reduction of α-syn phosphorylation at this specific residue after LRRK2 
inhibition.  Because the ability of LRRK2 to phosphorylate α-syn is still quite controversial, 
more studies will be required to clarify the role of LRRK2 on phosphorylation of α-syn, and to 
elucidate the efficacy of LRRK2-IN-1 in cell culture-based experiments. 
In vitro and in vivo studies have shown that both soluble and fibrillized α-syn can be a 
substrate for CK-2 at Ser129 (Okochi et al., 2000; Pronin et al., 2000; Takahashi et al., 2007; 
Waxman and Giasson, 2008; Qing et al., 2009a). Studies in cellular models demonstrated that 
activation or overexpression of CK-2 can strongly increase the phosphorylation of α-syn at 
Ser129 (Waxman and Giasson, 2008). Moreover, treatment with selective inhibitors of CK-2 
significantly reduced Ser129 α-syn phosphorylation (Okochi et al., 2000; Takahashi et al., 
2007; Sugeno et al., 2008; Waxman and Giasson, 2008; Waxman and Giasson, 2011).  
Takahashi and coworkers (2007) reported that cells exposed to FeCl2 promoted accumulation of 
Ser129 phosphorylated α-syn and CK-2 protein. They postulated that α-syn phosphorylation 
caused by FeCl2 was due to CK-2 upregulation. According to these authors, FeCl2 exposure 
evokes ROS production and consequently oxidative stress, which in turn upregulates CK-2 that 
increases Ser129 α-syn phosphorylation. Altogether, previous published data suggest that CK-2 
is a kinase important for α-syn phosphorylation induced by oxidative stress (Smith et al., 2005; 
Takahashi et al., 2007). Importantly, our results are in agreement with these findings indicating 
that CK-2 plays a crucial role in α-syn phosphorylation caused by Fe exposure. We 
demonstrated that CX-4945 inhibited CK-2-mediated phosphorylation of α-syn. Indeed, among 
the three kinase inhibitors tested to evaluate the role of their targets on α-syn phosphorylation, 
we believe that our results allow to conclude that CK-2 is the most effective kinase on α-syn 
phosphorylation at Ser129 in SH-SY5Y cells subjected to the noxious Fe stimulus, since 
inhibition of this kinase led to a more pronounced decrease in α-syn phosphorylation levels. 
This view is supported by the results from previous studies (Okochi et al., 2000; Smith et al., 
2005; Ishii et al., 2007; Takahashi et al., 2007). Moreover, as described previously, our results 
demonstrate that α-syn phosphorylation was increased in –Dox condition cultures with Fe 
stimulation. Such results might be explained by α-syn overexpression and oxidative stress 
triggered by Fe, that led to an increase in activity/levels of CK-2 protein (Takahashi et al., 
2007). Fe incubation did not increase CK-2 mRNA levels, thus its influence on CK-2 is likely 
due to suppression of protein degradation (Takahashi et al., 2007). 
Considering this part of the study, more studies will be required to perceive what is the role 
of CK-2 and other potential kinases in the context of α-syn (Ser129) phosphorylation and in PD 
pathogenesis, providing valuable insights for the development of novel PD therapies. 
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In conclusion, this work allowed us to better understand the potential kinases involved in α-
syn (Ser129) phosphorylation state as well as the possible protective role of GDNF as an 
important factor able to reduce α-syn phosphorylation induced by oxidative stress in the context 
of PD. Studies were performed in human SH-SY5Y neuroblastoma cell line overexpressing α-
syn in a Tet-Off regulated manner (in the absence of Dox), allowing the study of α-syn 
pathogenesis in PD. We defined nanomolar non-toxic concentrations of kinase inhibitors, which 
were used in this work to modulate oxidative stress-induced α-syn (Ser129) phosphorylation. 
Indeed, high concentrations were toxic and were linked to cell cycle arrest and apoptosis in a 
large number of cells. We showed that Fe (an oxidative stress inducer) exposure in –Dox cells 
can provoke an increase in α-syn phosphorylation at Ser129. Moreover, under non-stressed 
conditions (in the absence of Fe), GDNF can also induce α-syn (Ser129) phosphorylation. 
However, in the presence of Fe, this neurotrophic factor appears to contribute for the prevention 
of neurotoxicity, by both reducing α-syn phosphorylation imposed by Fe and possibly reducing 
oxidative stress. The effect of GDNF in cells overexpressing α-syn subjected to oxidative stress 
appears to occur through the early activation of PI3K/Akt signaling pathways, most probably by 
activation of the RET protein. Moreover, we showed that LRRK2 and CK-2 inhibitors can 
reduce the levels of Seri129 phosphorylated α-syn. Nevertheless, CK-2 seems to be the major 
and mostly accepted kinase able to promote the transfer of a phosphate group to Ser129 of α-
syn. By having CK-2 as the most promising therapeutic target and GDNF as a possible 
neuroprotective agent against increased α-syn phosphorylation induced by oxidative stress, this 
study took a step forward in the search for new therapeutic targets and control of PD cellular 
pathology. 
There are some key aspects that should be taking into consideration in future studies that 
may either reinforce our data or achieve new complementary findings. On the one hand, and 
taking into account both the toxicity of the inhibitors tested and the relevant role of kinase 
pathways, it is important to prove that some effects were indeed due to a selective kinases; in 
this regard, the role of certain kinases can be addressed through siRNAs. Moreover, it would be 
important to determine the role of such kinases on α-syn phosphorylation at Ser87, another 
potential regulated residue. Indeed, it would be interesting to explore whether Ser87 and/or 
Ser129 phosphorylated α-syn have implications in the formation of LB-like α-syn aggregates 
and toxicity in cells overexpressing α-syn, as model of PD pathogenesis. On the other hand, in 
order to prove if GDNF exerts protective effect upon α-syn phosphorylation, transfected cells 
for RET and GFRα1 receptors might be considered. In addition, analysis of activation of Erk 
signaling pathways and test of different concentrations of GDNF are also important, since 
GDNF effect is dose and cell type-dependent. Different Fe concentrations and exposure to 
different oxidative stress stimuli, such as hydrogen peroxide or mitochondrial inhibitors (e.g. 
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rotenone, a selective inhibitor of complex I) should be also considered. These experiments 
might be carried out in differentiated SH-SY5Y cells overexpressing α-syn and cells expressing 
mutant forms of α-syn (e.g. A53T) to mimic other PD familial forms. Last but not least, in 
future studies modulation of LRRK2 or CK-2 activity or expression (using selective inhibitors 
and/or siRNAs) might be tested in in vivo PD models (e.g. PD transgenic mice or mice treated 
with MPTP), in order to validate their beneficial effects. 
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